

Prof. RAMAZAN İDİLMAN

Personal Information

Office Phone: [+90 312 595 6293](tel:+903125956293)

Fax Phone: [+90 312 363 6213](tel:+903123636213)

Email: idilman@medicine.ankara.edu.tr

Web: <https://avesis.ankara.edu.tr/idilman>

International Researcher IDs

ORCID: 0000-0001-8840-5472

Publons / Web Of Science ResearcherID: AFL-0461-2022

Yoksis Researcher ID: 8789

Education Information

Post Doctorate of Medicine, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2001 - Continues
Undergraduate, Cukurova University, Tıp Fakültesi, Turkey 1986 - 1992

Research Areas

Gastroenterology and Hepatology

Academic Titles / Tasks

Professor, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 1992 - Continues

Advising Theses

İdilman R., Hastaneye yatan siroz hastalarında erken ve geç dönem mortaliteye etki eden faktörler, Expertise In Medicine, B.HAKTANIYAN(Student), 2022

İdilman R., Alkol ilişkili kronik karaciğer hastalığı seyrine etki eden faktörler, Expertise In Medicine, B.ALPER(Student), 2022

İDİLMAN R., Kronik hepatit B hastalarında entekavir ve tenofovir tedavi kesimi sonrası hepatit B relaps oranları ve relaps belirleyicilerinin saptanması, Expertise In Medicine, F.TUĞÇE(Student), 2020

İDİLMAN R., Alkol dışı yağlı karaciğer hastalığında kardiyak ve kardiyovasküler hastalık varlığının önceden saptanması: Subklinik myokardial disfonksiyon, Expertise In Medicine, B.BAHAR(Student), 2020

İDİLMAN R., Hepatit C virus enfeksiyonuna bağlı dekompanse sirotik ve karaciğer nakıl hastalarında sofosbuvir/ledipasvir tedavisinin etkinliği ve tolerabilitesi, Expertise In Medicine, C.EROL(Student), 2016

İDİLMAN R., Hepatit B enfeksiyonuna bağlı sirotik hastalarda uzun süreli oral antiviral ajan kullanımının hastalık seyrine etkisi, Expertise In Medicine, G.KILIÇ(Student), 2015

İDİLMAN R., Portal hipertansiyonlu hastalarda transjuguler intrahepatik portosistemik şantın böbrek fonksiyonları bozukluğu ve renal resistivite indeksi üzerine etkileri, Expertise In Medicine, G.CENGİZ(Student), 2010

İDİLMAN R., HBE antijen negatif kronik Hepatit B'li hastalarda Lamivudin tedavisinin etkinliği, Expertise In Medicine, Y.BOZKUŞ(Student), 2009

İDİLMAN R., Kronik hepatit C'li hastalarda karaciğer fibrozisini göstermede kullanılan biyokimyasal belirteçler ile

karaciğer biyopsisinin tanışal değerliliklerinin karşılaştırılması, Expertise In Medicine, D.MIZRAK(Student), 2008
İDİLMAN R., Non-alkolik yağlı karaciğeri olanlarda endotelyal fonksiyon bozukluğu ve kardiyovasküler risk profilinin belirlenmesi: metabolik sendrom birlikteliğinin etkinliği, M.SAYKI(Student), 2008
İDİLMAN R., Kronik hepatit C'li hastalarda karaciğer yağlanmasıının pegile-interferon ile kombiné antiviral tedavi yanıtına etkisi, Expertise In Medicine, Ş.ÇOBAN(Student), 2006

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease**
Noureddin N., Huang D. Q., Bettencourt R., Siddiqi H., Majzoub A. M., Nayfeh T., Tamaki N., Izumi N., Nakajima A., İDİLMAN R., et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024 (SCI-Expanded)
- II. **Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.**
Lee S. W., Huang D. Q., Bettencourt R., Ajmera V., Tincopa M., Noureddin N., Amangurbanova M., Siddiqi H., Madamba E., Majzoub A. M., et al.
Alimentary pharmacology & therapeutics, vol.59, no.1, pp.80-88, 2024 (SCI-Expanded)
- III. **Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D**
Anastasiou O. E., Caruntu F. A., Curescu M. G., Yalcin K., Akarca U. S., GÜREL S., Zeuzem S., Erhardt A., Lüth S., Papatheodoridis G. V., et al.
Liver International, vol.44, no.1, pp.139-147, 2024 (SCI-Expanded)
- IV. **Geographic disparities in access to liver transplant for advanced cirrhosis: Time to ring the alarm!**
Bajaj J. S., Choudhury A., Kumaran V., Wong F., Seto W. K., Alvares-Da-Silva M. R., Desalgn H., Hayes P. C., İDİLMAN R., Topazian M., et al.
American Journal of Transplantation, 2024 (SCI-Expanded)
- V. **Demonstration of therapy response to radioembolization with ^{90}Y resin microspheres on ^{68}Ga -PSMA PET/MRI in a patient with hepatocellular carcinoma**
Özkan E., Demir B., Kuru Öz D., Soydal Ç., Dursun E., Çelebioğlu E. C., İdilman R., Küçük N. Ö.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.51, no.1, pp.316-317, 2023 (SCI-Expanded)
- VI. **Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study.**
Kim B. K., Bergstrom J., Loomba R., Tamaki N., Izumi N., Nakajima A., Idilman R., Gumussoy M., Oz D., Erden A., et al.
Hepatology (Baltimore, Md.), vol.78, no.6, pp.1858-1866, 2023 (SCI-Expanded)
- VII. **Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories.**
Razavi-Shearer D., Child H., Razavi-Shearer K., Voeller A., Razavi H., Buti M., Tacke F., Terrault N., Zeuzem S., Abbas Z., et al.
Journal of hepatology, 2023 (SCI-Expanded)
- VIII. **A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone**
Duman S., Kuru D., Gumussoy M., KİREMİTCİ S., GÖKCAN H., Ulas B., Ellik Z., Ozercan M., ER R. E., Karakaya F., et al.
EUROPEAN RADIOLOGY, 2023 (SCI-Expanded)
- IX. **Diagnosis and Treatment of Autoimmune Hepatitis: Questions, Answers, and Illustrative Cases: Endorsed by Autoimmune Liver Diseases Special Interest Group, Turkish Association for the Study of Liver**
Özaslan E., Günşar F., ÇİFCİBAŞI ÖRMECİ A., Hatemi İ., Efe C., AKYOL G., Turhan N., Barbet F. Y., SAĞOL Ö., Ataizi Çelikel Ç., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.34, 2023

- (SCI-Expanded)
- X. **MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses.**
Noureddin N., Ajmera V., Bergstrom J., Bettencourt R., Huang D. Q., Siddiqi H., Majzoub A. M., Nayfeh T., Tamaki N., Izumi N., et al.
Alimentary pharmacology & therapeutics, vol.58, no.9, pp.856-865, 2023 (SCI-Expanded)
 - XI. **A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease**
Romero-Gómez M., Lawitz E., Shankar R. R., Chaudhri E., Liu J., Lam R. L., Kaufman K. D., Engel S. S., Bruzone S. O., Coronel M. J., et al.
Journal of Hepatology, vol.79, no.4, pp.888-897, 2023 (SCI-Expanded)
 - XII. **Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.**
Huang D. Q., Noureddin N., Ajmera V., Amangurbanova M., Bettencourt R., Truong E., Gidener T., Siddiqi H., Majzoub A. M., Nayfeh T., et al.
The lancet. Gastroenterology & hepatology, vol.8, no.9, pp.829-836, 2023 (SCI-Expanded)
 - XIII. **Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial**
Dinkelborg K., Kahlhöfer J., Dörge P., Yurdaydin C., Hardtke S., Caruntu F. A., Curescu M. G., Yalcin K., Akarca U. S., GÜREL S., et al.
Liver International, vol.43, no.8, pp.1663-1676, 2023 (SCI-Expanded)
 - XIV. **Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium**
Bajaj J. S., Choudhury A. K., Xie Q., Kamath P. S., Topazian M., Hayes P. C., Torre A., Desalegn H., İDİLMAN R., Cao Z., et al.
The Lancet Gastroenterology and Hepatology, vol.8, no.7, pp.611-622, 2023 (SCI-Expanded)
 - XV. **Development of metabolic disorders in transplant recipients**
Erdemir G., GÖKCAN H., GÜRSOY ÇORUH A., GÜLPINAR B., Ellik Z. M., Gumussoy M., Duman S., BODAKÇI E., İDİLMAN R.
JOURNAL OF HEPATOLOGY, vol.78, 2023 (SCI-Expanded)
 - XVI. **Nosocomial infections in cirrhosis are unpredictable and vary based on region of the world: CLEARED study**
Bajaj J. S., Wong F., Xie Q., Kamath P. S., Topazian M., Sarin S. K., Kumar S., Marciano S., Tudehope F., Gibson R., et al.
JOURNAL OF HEPATOLOGY, vol.78, 2023 (SCI-Expanded)
 - XVII. **Availability and affordability of services affects outcome in hospitalized patients with cirrhosis- results from CLEARED consortium**
Choudhury A., Xie Q., Topazian M., Sarin S. K., Hayes P., Torre A., Desalegn H., İDİLMAN R., Cao Z., Kumar S., et al.
JOURNAL OF HEPATOLOGY, vol.78, 2023 (SCI-Expanded)
 - XVIII. **Stratification of liver fat content in non-alcoholic steatohepatitis patients with significant liver fibrosis using the MEFIB-Index and MRI-PDFF and its association with hepatocellular carcinoma, decompensation, and mortality**
Lee S. W., Huang D., Ajmera V., Tincopa M., Bergstrom J., Noureddin N., Amangurbanova M., Siddiqi H., Madamba E., Majzoub A., et al.
JOURNAL OF HEPATOLOGY, vol.78, 2023 (SCI-Expanded)
 - XIX. **Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D**
Anastasiou O. A., Caruntu F. A., Curescu M. G., YALÇIN K., AKARCA U. S., GÜREL S., Zeuzem S., Erhardt A., Lueth S., Papatheodoridis G., et al.
JOURNAL OF HEPATOLOGY, vol.78, 2023 (SCI-Expanded)
 - XX. **The role of PAGE-B score in predicting the development of hepatocellular cancer in patients with chronic delta hepatitis**
KESKİN O., Kalkan C., ÖZTÜRK B., Caliskan A., Sahin H., Gumussoy M., Yurdcu E., Bozdayi M., Akyildiz M., Zeybel M., et al.

- al.
JOURNAL OF HEPATOLOGY, vol.78, 2023 (SCI-Expanded)
- XXI. **Identification of risk factors for alcohol relapse in liver transplant patients with alcohol-related liver disease**
Turan D., GÜNSAR F., Harputluoglu M., Kabacam G., Gokcan H., Akyildiz M., AKARSU M., Adali G., Ari D., Turan I., et al.
JOURNAL OF HEPATOLOGY, vol.78, 2023 (SCI-Expanded)
- XXII. **Non-invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta**
Kalkan Ç., Yilmaz Y., Erdogan B. D., SAVAŞ B., Yurdcu E., Çalışkan A., Keskin O., Gencdal G., Zeybel M., TÖRÜNER M., et al.
Journal of Viral Hepatitis, vol.30, no.5, pp.406-416, 2023 (SCI-Expanded)
- XXIII. **Determining Subclinical Cardiovascular and Cardiac Diseases in Patients with Non-Alcoholic Fatty Liver Disease**
Karaoğlan B. B., Tulunay C., Uzun Ç., Peker E., Özyüncü N., Ellik Z., Kuru D., Turhan S., Savaş B., Erden A., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.34, no.3, pp.242-253, 2023 (SCI-Expanded)
- XXIV. **Management of Biliary Complications in Liver Transplant Recipients with Duct-To-Duct Anastomosis: A Single-Center Experience**
KARAKAYA M. F., Er E., Kırımkıroğlu O., Gümüşsoy M., BODAKÇI E., Özercan M., DOĞANAY ERDOĞAN B., GÖKCAN H., KOLOĞLU M., Karayalçın K., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.34, no.2, pp.177-181, 2023 (SCI-Expanded)
- XXV. **A global action agenda for turning the tide on fatty liver disease**
Lazarus J. V., Mark H. E., Allen A. M., Arab J. P., Carrieri P., Noureddin M., Alazawi W., Alkhouri N., Alqahtani S. A., Anstee Q. M., et al.
Hepatology, 2023 (SCI-Expanded)
- XXVI. **Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome**
Efe C., Kulkarni A. V., Terzioli Beretta-Piccoli B., Magro B., Stättermayer A., Cengiz M., Clayton-Chubb D., Lammert C., Bernsmeier C., Gül Ö., et al.
Hepatology, vol.76, no.6, pp.1576-1586, 2022 (SCI-Expanded)
- XXVII. **Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study**
Gumussoy M., Koc O., KARATAŞ G., Ozercan M., Ellik Z., DUMAN S., KİREMİTCİ S., GÖKCAN H., ELHAN A. H., SAVAŞ B., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.34, no.11, pp.1172-1177, 2022 (SCI-Expanded)
- XXVIII. **MEFIB AND MAST SCORES ASSESSMENT OF INCIDENT LIVER-RELATED OUTCOMES IN NONALCOHOLIC FATTY LIVER DISEASE: AN INDIVIDUAL PATIENT META-ANALYSIS**
Noureddin N., Ajmera V., Bergstrom J., Huang D., Siddiqi H., Majzoub A., Nayfeh T., Tamaki N., Izumi N., Nakajima A., et al.
HEPATOLOGY, vol.76, 2022 (SCI-Expanded)
- XXIX. **Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis**
Cavazos K., Eswaran S., Maidlow C., KEKLİK KARADAĞ F., İDİLMAN R., İDİLMAN İ. S., Miller I., Shammo J., Reau N., Ustun C.
BLOOD ADVANCES, vol.6, no.20, pp.5630-5633, 2022 (SCI-Expanded)
- XXX. **DIFFERENCES IN MORTALITY RATES IN INPATIENTS WITH CIRRHOSIS DEPENDS ON THE LOW, MIDDLE OR HIGH INCOME COUNTRY LOCATION: MULTI-NATIONAL CLEARED CONSORTIUM EXPERIENCE**
Bajaj J. S., Wong F., Xie Q., Topazian M., Aldo T., İDİLMAN R., Alvares-Da-Silva M. R., Hayes P. C., George T., Kouacou M. J. D. L. E., et al.
HEPATOLOGY, vol.76, 2022 (SCI-Expanded)

- XXXI. LOW SERUM ALBUMIN AT ADMISSION IS ASSOCIATED WITH MORTALITY AMONG INPATIENTS WITH CIRRHOSIS: A MULTI-NATIONAL EXPERIENCE**
Wong F., Choudhury A. K., Xie Q., İDİLMAN R., George J., Kouacou M. J. D. L. E., Allah B. H., Lah P. C. R., Debzi N., Desalegn H., et al.
HEPATOLOGY, vol.76, 2022 (SCI-Expanded)
- XXXII. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis**
Efe C., Taşçilar K., Gerussi A., Bolis F., Lammert C., Ebik B., Stättermayer A. F., Cengiz M., Gökçe D. T., Cristoferi L., et al.
Journal of Autoimmunity, vol.132, 2022 (SCI-Expanded)
- XXXIII. Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants.**
Ajmera V., Kim B. K., Yang K., Majzoub A. M., Nayfeh T., Tamaki N., Izumi N., Nakajima A., Idilman R., Gumussoy M., et al.
Gastroenterology, vol.163, no.4, pp.1079, 2022 (SCI-Expanded)
- XXXIV. NATURAL DISEASE OUTCOMES IN PATIENT WITH NONALCOHOLIC FATTY LIVER DISEASE: A STUDY WITH PAIRED LIVER BIOPSIES**
Gumussoy M., Gokce D. T., Ekelik M., KİREMİTCİ S., Bodakci E., DUMAN S., Ellik Z. M., GÜVENİR S. T., ER R. E., KARAKAYA M. F., et al.
HEPATOLOGY, vol.76, 2022 (SCI-Expanded)
- XXXV. EFFECT OF PROGNOSTIC NONINVASIVE TESTS ON DISEASE OUTCOME OF ALCOHOL-RELATED LIVER DISEASE**
Zengin B. A., Gumussoy M., Duman S., Bodakçı E., Güvenir S. T., Ellik Z., Ozercan M., Er R. E., Karakaya M. F., Sumer H., et al.
HEPATOLOGY, vol.76, 2022 (SCI-Expanded)
- XXXVI. FUNCTIONAL CURE WITH LONAFARNIB-BASED THERAPY IN CHRONIC HEPATITIS DELTA**
Yurdaydin C., Yurdcu E., Gumussoy M., KESKİN O., Gencdal G., Akyildiz M., Zeybel M., İDİLMAN R., Bozdayi M., Choong I., et al.
HEPATOLOGY, vol.76, 2022 (SCI-Expanded)
- XXXVII. Liver stiffness on magnetic resonance elastography and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants**
Ajmera V., Yang K., Kim B. K., Majzoub A., Tamaki N., Nakajima A., İDİLMAN R., Gumussoy M., Oz D., ERDEN G. A., et al.
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- XXXVIII. Effectiveness of MRI methods in the assessment of hepatic steatosis in living liver donors**
KURU ÖZ D., Ellik Z. M., Coruh A. G., ADIGÜZEL M., Gumussoy M., DUMAN S., ER R. E., Kirimker O., BALCI D., GÖKCAN H., et al.
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- XXXIX. The course of COVID-19 infection in patients with chronic hepatitis B and Delta**
PARLAR Y. E., KESKİN O., KIRMIZIGÜL B., Gencdal G., Zeybel M., Gumussoy M., İDİLMAN R., Yurdaydin C.
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- XL. Chronic hepatitis delta with normal ALT and hepatitis D viremia**
Arici S., Palom A., Gumussoy M., İDİLMAN R., Gencdal G., Esteban R., Zeybel M., Buti M., Yurdaydin C.
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- XLI. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis**
Yurdaydin C., Keskin O., Yurdcu E., Caliskan A., Onem S., Karakaya F., Kalkan C., Karatayli E., Karatayli S., Choong I., et al.
HEPATOLOGY, vol.75, no.6, pp.1551-1565, 2022 (SCI-Expanded)
- XLII. Global multi-stakeholder endorsement of the MAFLD definition**

- Méndez-Sánchez N., Bugianesi E., Gish R. G., Lammert F., Tilg H., Nguyen M. H., Sarin S. K., Fabrellas N., Zelber-Sagi S., Fan J., et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY, vol.7, no.5, pp.388-390, 2022 (SCI-Expanded)
- XLIII. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis**
Efe C., Lammert C., Taşçılar K., Dhanasekaran R., Ebik B., Higuera-de la Tijera F., Çalışkan A. R., Peralta M., Gerussi A., Massoumi H., et al.
Liver International, vol.42, no.3, pp.607-614, 2022 (SCI-Expanded)
- XLIV. Evaluation of Magnetic Resonance Elastography and Transient Elastography for Liver Fibrosis and Steatosis Assessments in the Liver Transplant Setting**
Ellik Z. M., İDİLMAN İ. S., Kartal A., Balaban Y., ELHAN A. H., KARÇAALTINCABA M., ÖZKAN H., İDİLMAN R.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.33, no.2, pp.153-160, 2022 (SCI-Expanded)
- XLV. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B**
Kim H. Y., Lampertico P., Nam J. Y., Lee H., Kim S. U., Sinn D. H., Seo Y. S., Lee H. A., Park S. Y., Lim Y., et al.
JOURNAL OF HEPATOLOGY, vol.76, no.2, pp.311-318, 2022 (SCI-Expanded)
- XLVI. Advancing the global public health agenda for NAFLD: a consensus statement**
Lazarus J. V., Mark H. E., Anstee Q. M., Arab J. P., Batterham R. L., Castera L., Cortez-Pinto H., Crespo J., Cusi K., Dirac M. A., et al.
Nature Reviews Gastroenterology and Hepatology, vol.19, no.1, pp.60-78, 2022 (SCI-Expanded)
- XLVII. Determination of Turkish norms of psychometric tests for diagnosing minimal hepatic encephalopathy and proposal of a high sensitive screening test battery**
ÖZBAŞ B., Keskin O., Hecker H., Karahan I., ÖZBAŞ C., Kalkan C., Kartal A., Onder F. O., Oncu B. K., Gencdal G., et al.
HEPATOLOGY INTERNATIONAL, vol.15, pp.1442-1455, 2021 (SCI-Expanded)
- XLVIII. Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study**
AKARCA U. S., Unsal B., Sezgin O., Yalcin K., Akdogan M., Gonen C., Gunduz F., Ozenirler S., SONSUZ A., DİNÇER D., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.12, pp.1019-1028, 2021 (SCI-Expanded)
- XLIX. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B**
Jang H., Yoon J. S., Park S. Y., Lee H. A., Jang M., Kim S. U., Sinn D. H., Seo Y. S., Kim H. Y., Kim S. E., et al.
Clinical Gastroenterology and Hepatology, vol.74, 2021 (SCI-Expanded)
- L. Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation**
AKARSU M., Onem S., TURAN İ., Adali G., Akdogan M., Akyildiz M., ALADAĞ M., Balaban Y., Danis N., Dayangac M., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.9, pp.712-719, 2021 (SCI-Expanded)
- LI. The feasibility of T2 mapping in the assessment of hepatic steatosis, inflammation, and fibrosis in patients with non-alcoholic fatty liver disease: a preliminary study.**
Idilman I. S., Celik A., Savas B., Idilman R., Karcaaltincaba M.
Clinical radiology, vol.76, no.9, 2021 (SCI-Expanded)
- LII. Covid-19 in Liver Transplant Recipients: A National Cohort**
Kabacam G., TURAN İ., KIYICI M., Ellik Z. M., DOLU S., Dayangac M., Ari D., Gokce D. T., YILDIRIM A. E., Gencdal G., et al.
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- LIII. Outcomes and characteristics of hepatocellular carcinomas (HCC) in Caucasian chronic hepatitis B (CHB) patients treated with long-term entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy**
Papatheodoridis G., Dalekos G., İDİLMAN R., Sypsa V., Buti M., Calleja Panero J. L., Goulis I., Sonneveld M., van Bommel F., Manolakopoulos S., et al.
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)

- LIV. **Association between non-alcoholic fatty liver disease and extrahepatic malignancy**
Gumussoy M., İDİLMAN R., GÖKCAN H., Gokce D. T., Ulas B. B., Koc O., KARATAŞ G., BODAKÇI E., Ozercan M., Karakaya F., et al.
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- LV. **Etiology of Cirrhosis in Turkey: A National Cohort Study**
YILDIRIM A. E., ÜÇBİLEK E., Oruncu M. B., TURAN İ., DEMİR M., Koksal A., UYANIKOĞLU A., Yilmaz N., AKARSU M., Tozlu M., et al.
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- LVI. **The artificial intelligence-driven model for prediction of hepatocellular carcinoma development in chronic hepatitis B patients: Derivation and validation using 11, 111 patients from Asian and Caucasian cohorts**
Kim H. Y., Lampertico P., Nam J. Y., Lee H., Kim S. U., Jang E. S., Lee H. A., Park S. Y., Seo Y. S., Lim Y., et al.
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- LVII. **Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study**
Efe C., Dhanasekaran R., Lammert C., Ebik B., Higuera-de la Tijera F., Aloman C., Caliskan A. R., Peralta M., Gerussi A., Massoumi H., et al.
HEPATOLOGY, vol.73, no.6, pp.2099-2109, 2021 (SCI-Expanded)
- LVIII. **Natural History of Cirrhosis: Changing Trends in Etiology Over the Years**
İDİLMAN R., Aydogan M., Oruncu M. B., Kartal A., ELHAN A. H., Ellik Z., Gumussoy M., Er R. E., Ozercan M., DUMAN S., et al.
DIGESTIVE DISEASES, vol.39, no.4, pp.358-365, 2021 (SCI-Expanded)
- LIX. **Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study**
Bremer B., Anastasiou O. E., Hardtke S., Caruntu F. A., Curescu M. G., YALÇIN K., AKARCA U. S., GÜREL S., Zeuzem S., Erhardt A., et al.
LIVER INTERNATIONAL, vol.41, no.2, pp.295-299, 2021 (SCI-Expanded)
- LX. **MRI quantification techniques in fatty liver: the diagnostic performance of hepatic T1, T2, and stiffness measurements in relation to the proton density fat fraction**
Erden A., KURU ÖZ D., PEKER E., Kul M., Ates F. S. O., Erden I., İDİLMAN R.
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, vol.27, no.1, pp.7-14, 2021 (SCI-Expanded)
- LXI. **Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta**
Wranke A., Hardtke S., Heidrich B., Dalekos G., YALÇIN K., Tabak F., GÜREL S., Cakaloglu Y., AKARCA U. S., Lammert F., et al.
JOURNAL OF VIRAL HEPATITIS, vol.27, no.12, pp.1359-1368, 2020 (SCI-Expanded)
- LXII. **aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis C**
Fan R., Papatheodoridis G., Sun J., Innes H., Toyoda H., Xie Q., Mo S., Sypsa V., Guha I. N., Kumada T., et al.
JOURNAL OF HEPATOLOGY, vol.73, no.6, pp.1368-1378, 2020 (SCI-Expanded)
- LXIII. **Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and Omibitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience**
Degertekin B., DEMİR M., AKARCA U. S., Kani H. T., ÜÇBİLEK E., Yildirim E., Guzelbulut F., BALKAN A., Vatansever S., Danis N., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.31, no.12, pp.883-893, 2020 (SCI-Expanded)
- LXIV. **Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B**
Papatheodoridis G., Dalekos G. N., İDİLMAN R., Sypsa V., Van Boemmel F., Buti M., Calleja J. L., Goulis J., Manolakopoulos S., Loglio A., et al.
JOURNAL OF HEPATOLOGY, vol.73, no.5, pp.1037-1045, 2020 (SCI-Expanded)
- LXV. **Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B**
Papatheodoridis G. V., Sypsa V., Dalekos G. N., Yurdaydin C., Van Boemmel F., Buti M., Calleja J. L., Chi H., Goulis J., Manolakopoulos S., et al.

- JOURNAL OF HEPATOLOGY, vol.72, no.6, pp.1088-1096, 2020 (SCI-Expanded)
- LXVI. **The COVID-19 pandemic: Clinical practice advice for gastroenterologists, hepatologists, and liver transplant specialists**
Kabacam G., Dayangac M., ÜÇBİLEK E., Ercin C. N., Gunsar F., Akyilchz M., AKARSU M., Demira M., Kaymakoglu S., Karasus Z., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.31, no.5, pp.348-355, 2020 (SCI-Expanded)
- LXVII. **A micro-elimination approach to addressing hepatitis C in Turkey**
İDİLMAN R., Razavi H., Robbins-Scott S., AKARCA U. S., Ormeci N., Kaymakoglu S., AYGEN B., Tozun N., Guner R., Bodur H., et al.
BMC HEALTH SERVICES RESEARCH, vol.20, no.1, 2020 (SCI-Expanded)
- LXVIII. **Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis**
Cox I. J., İDİLMAN R., Fagan A., Turan D., Ajayi L., Le Guennec A. D., Taylor-Robinson S. D., Karakaya F., Gavis E., Andrew Atkinson R., et al.
LIVER INTERNATIONAL, no.2, pp.416-427, 2020 (SCI-Expanded)
- LXIX. **Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort**
İDİLMAN R., DEMİR M., ALADAĞ M., Erol C., Cavus B., Iliaz R., Koklu H., Cakaloglu Y., Sahin M., ERSÖZ G., et al.
JOURNAL OF VIRAL HEPATITIS, vol.26, no.6, pp.666-674, 2019 (SCI-Expanded)
- LXX. **Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial**
Wedemeyer H., Yurdaydin C., Hardtke S., Caruntu F. A., Curescu M. G., YALÇIN K., AKARCA U. S., GÜREL S., Zeuzem S., Erhardt A., et al.
LANCET INFECTIOUS DISEASES, vol.19, no.3, pp.275-286, 2019 (SCI-Expanded)
- LXXI. **Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up**
van Campenhout M. J. H., Brouwer W. P., Xie Q., Guo S., Chi H., Qi X., TABAK Ö. F., Streinu-Cercel A., Wang J., Zhang N., et al.
JOURNAL OF VIRAL HEPATITIS, vol.26, no.1, pp.109-117, 2019 (SCI-Expanded)
- LXXII. **Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib**
Atilla P. A., Yalciner M., Atilla E., İDİLMAN R., BEKSAÇ M.
TURKISH JOURNAL OF HEMATOLOGY, vol.36, no.4, pp.266-273, 2019 (SCI-Expanded)
- LXXIII. **Health-related Quality of Life of Liver Donors: A Prospective Longitudinal Study**
Hesimov I., Kirimker E. O., Duman B., Keskin O., ÇETİN KAYA Ö. A., Hayme S., ÜSTÜNER E., Idilman R., Yurdaydin C., Dokmeci A., et al.
TRANSPLANTATION PROCEEDINGS, vol.50, no.10, pp.3076-3081, 2018 (SCI-Expanded)
- LXXIV. **Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy**
Lutterkort G. L., Wranke A., Hengst J., Yurdaydin C., Stift J., Bremer B., Hardtke S., Keskin O., Idilman R., Manns M. P., et al.
JOURNAL OF VIRAL HEPATITIS, vol.25, no.11, pp.1384-1394, 2018 (SCI-Expanded)
- LXXV. **Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort**
Bajaj J. S., İDİLMAN R., Mabudian L., Hood M., Fagan A., Turan D., White M. B., Karakaya F., Wang J., ATALAY R., et al.
HEPATOLOGY, no.1, pp.234-247, 2018 (SCI-Expanded)
- LXXVI. **Serum biomarkers for the evaluation of liver fibrosis: The need for better tests**
Zeybel M., İDİLMAN R.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.29, no.4, pp.377-378, 2018 (SCI-Expanded)
- LXXVII. **Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population**

- Papatheodoridis G. V., Sypsa V., Dalekos G., Yurdaydin C., van Boemmel F., Buti M., Gouli J., Calleja J. L., Chi H., Manolakopoulos S., et al.
JOURNAL OF HEPATOLOGY, vol.68, no.6, pp.1129-1136, 2018 (SCI-Expanded)
- LXXVIII. **Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease**
Yurdaydin C., Keskin O., Kalkan C., Karakaya F., Caliskan A., Kabacam G., ÖNDER F. O., Karatayli S., Karatayli E., Deda X., et al.
JOURNAL OF INFECTIOUS DISEASES, no.8, pp.1184-1192, 2018 (SCI-Expanded)
- LXXIX. **Optimizing Ionafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study**
Yurdaydin C., Keskin O., Kalkan C., Karakaya F., Caliskan A., Karatayli E., Karatayli S., BOZDAYI A. M., Koh C., Heller T., et al.
HEPATOLOGY, no.4, pp.1224-1236, 2018 (SCI-Expanded)
- LXXX. **Recommendation for treatment of hepatitis C virus infection**
KAYMAKOĞLU S., Koksal I., KAYMAKOĞLU S., Tabak F., AKARCA U. S., Akbulut A., AKYÜZ F., Bodur H., ÇAĞATAY A. A., Dincer D., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, 2017 (SCI-Expanded)
- LXXXI. **Diagnosis, management and treatment of hepatitis delta virus infection: Turkey 2017 Clinical Practice Guidelines**
Yurdaydin C., Tabak F., KAYMAKOĞLU S., TABAK Ö. F., Akarsu M., Akinci E. G., Akkiz H., Alkim C., Cekin A. H., Cuvalci N. O., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, 2017 (SCI-Expanded)
- LXXXII. **Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines**
TABAK Ö. F., Yurdaydin C., KAYMAKOĞLU S., Tabak F., Akarsu M., Akinci E. G., Akkiz H., Alkim C., Cekin A. H., Cuvalci N. O., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, 2017 (SCI-Expanded)
- LXXXIII. **Turkey 2017 Clinical Practice Guidelines on recommendations for screening diagnosing and managing hepatitis C virus**
İdilman R., Baykam N., KAYMAKOĞLU S., Tabak F., Bahcecioglu H. I., Bektas A., Bulut C., Gunsar F., Inan D., Karaosmanoglu H. K., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, 2017 (SCI-Expanded)
- LXXXIV. **Management of special patient groups with hepatitis B virus infection: The EASL 2017 Clinical Practice Guidelines**
İDİLMAN R.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, no.6, pp.518-521, 2017 (SCI-Expanded)
- LXXXV. **The Risk of Hepatocellular Carcinoma Decreases After the First 5 Years of Entecavir or Tenofovir in Caucasians With Chronic Hepatitis B**
Papatheodoridis G. V., İDİLMAN R., Dalekos G. N., Buti M., Chi H., van Boemmel F., Luis Calleja J., Sypsa V., Gouli J., Manolakopoulos S., et al.
HEPATOLOGY, vol.66, no.5, pp.1444-1453, 2017 (SCI-Expanded)
- LXXXVI. **The summarized of EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection**
İDİLMAN R.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, no.5, pp.412-416, 2017 (SCI-Expanded)
- LXXXVII. **Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients With Chronic Hepatitis Delta Virus Infection**
Canini L., Koh C., Cotler S. J., Uprichard S. L., Winters M. A., Han M. A. T., Kleiner D. E., İDİLMAN R., Yurdaydin C., Glenn J. S., et al.
HEPATOLOGY COMMUNICATIONS, vol.1, no.4, pp.288-292, 2017 (SCI-Expanded)
- LXXXVIII. **Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study**

- Blach S., Zeuzem S., Manns M., Altraif I., Duberg A., Muljono D. H., Waked I., Alavian S. M., Lee M., Negro F., et al. *The Lancet Gastroenterology and Hepatology*, vol.2, no.3, pp.161-176, 2017 (SCI-Expanded)
- LXXXIX. **Non-invasive fibrosis score for hepatitis delta**
Lutterkort G. L., Wranke A., Yurdaydin C., Budde E., Westphal M., Lichtinghagen R., Stift J., Bremer B., Hardtke S., Keskin O., et al.
LIVER INTERNATIONAL, vol.37, no.2, pp.196-204, 2017 (SCI-Expanded)
- XC. **Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up**
Karakaya F., Ozer S., Kalkan C., Tuzun E. A., Caliskan A., Keskin O., Kabacam G., Karatayli S., Karatayli E., BOZDAYI A. M., et al.
ANTIVIRAL THERAPY, no.7, pp.559-570, 2017 (SCI-Expanded)
- XCI. **Daclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1b Infection: Results of Turkish Early Access Program**
Koklu S., Koksal I., AKARCA U. S., BALKAN A., Guner R., Demirezen A., Sahin M., AKHAN S., Ozaras R., İDİLMAN R. *ANNALS OF HEPATOLOGY*, vol.16, no.1, pp.71-76, 2017 (SCI-Expanded)
- XCII. **Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B**
Marcellin P., Ahn S. H., Chuang W. -, Hui A. J., TABAK Ö. F., Mehta R., Petersen J., Lee C. -, Ma X., Caruntu F. A., et al. *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*, vol.44, no.9, pp.957-966, 2016 (SCI-Expanded)
- XCIII. **The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence**
İDİLMAN R., Akyildiz M., Keskin O., Gungor G., Yilmaz T. U., Kalkan C., Dayangac M., ÇINAR K., BALCI D., Hazinedaroglu S. M., et al.
CLINICAL TRANSPLANTATION, vol.30, no.10, pp.1216-1221, 2016 (SCI-Expanded)
- XCIV. **Stone-containing Cystic Mass at the Portal Hilus of the Liver in an Asymptomatic Young Female Patient Duplication of the Gallbladder**
İDİLMAN R., Erden A., Karakaya F.
GASTROENTEROLOGY, no.2, 2016 (SCI-Expanded)
- XCV. **Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients**
SOYDAL Ç., Arslan M. F., KÜÇÜK N. Ö., İDİLMAN R., Bilgic S.
NUCLEAR MEDICINE COMMUNICATIONS, vol.37, no.6, pp.646-649, 2016 (SCI-Expanded)
- XCVI. **PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy**
Papatheodoridis G., Dalekos G., Sypsa V., Yurdaydin C., Buti M., Gouli J., Luis Calleja J., Chi H., Manolakopoulos S., Mangia G., et al.
JOURNAL OF HEPATOLOGY, vol.64, no.4, pp.800-806, 2016 (SCI-Expanded)
- XCVII. **A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease**
İDİLMAN İ. S., Keskin O., Celik A., SAVAŞ B., ELHAN A. H., İDİLMAN R., KARÇAALTINCABA M.
ACTA RADIOLOGICA, vol.57, no.3, pp.271-278, 2016 (SCI-Expanded)
- XCVIII. **Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome**
Keskin O., Wedemeyer H., Tuzun A., Zachou K., Deda X., Dalekos G. N., Heidrich B., Pehlivan S., Zeuzem S., YALÇIN K., et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.13, no.13, pp.2342-2351, 2015 (SCI-Expanded)
- XCIX. **Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial**
Koh C., Canini L., Dahari H., Zhao X., Uprichard S. L., Haynes-Williams V., Winters M. A., Subramanya G., Cooper S. L., Pinto P., et al.
LANCET INFECTIOUS DISEASES, vol.15, no.10, pp.1167-1174, 2015 (SCI-Expanded)

- C. **Therapy of Delta Hepatitis**
Yurdaydin C., İDİLMAN R.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, vol.5, no.10, 2015 (SCI-Expanded)
- CI. **Sequential development of acute autoimmune hepatitis may lead to a serious clinical picture in primary biliary cirrhosis**
Keskin O., İDİLMAN R.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.27, no.10, pp.1228-1229, 2015 (SCI-Expanded)
- CII. **Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease**
İDİLMAN İ. S., Tuzun A., SAVAŞ B., ELHAN A. H., Celik A., İDİLMAN R., KARÇAALTINCABA M.
ABDOMINAL IMAGING, vol.40, no.6, pp.1512-1519, 2015 (SCI-Expanded)
- CIII. **Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease**
İdilman İ. S., Tüzün A. E., Savaş B., Elhan A. H., Çelik A., İdilman R., Karçaaltıncaba M.
ABDOMINAL IMAGING, vol.40, no.6, pp.1512-1519, 2015 (SCI-Expanded)
- CIV. **Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy**
SOYDAL Ç., Keskin O., KÜÇÜK N. Ö., ÖZKAN E., Bilgic S., İDİLMAN R., KIR K. M.
ANNALS OF NUCLEAR MEDICINE, vol.29, no.5, pp.426-430, 2015 (SCI-Expanded)
- CV. **Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting**
Idilman R., Gunsar F., Koruk M., Keskin O., Meral C. E., Gulsen M., ELHAN A. H., AKARCA U. S., Yurdaydin C.
JOURNAL OF VIRAL HEPATITIS, vol.22, no.5, pp.504-510, 2015 (SCI-Expanded)
- CVI. **Adding Pegylated Interferon to Entecavir for Hepatitis B e Antigen-Positive Chronic Hepatitis B: A Multicenter Randomized Trial (ARES Study)**
Brouwer W. P., Xie Q., Sonneveld M. J., Zhang N., Zhang Q., TABAK Ö. F., Streinu-Cercel A., Wang J., İDİLMAN R., Reesink H. W., et al.
HEPATOLOGY, vol.61, no.5, pp.1512-1522, 2015 (SCI-Expanded)
- CVII. **Nonalcoholic fatty liver disease is associated with significant coronary artery disease in type 2 diabetic patients: A computed tomography angiography study**
İdilman R., Akata D., Hazirolan T., Doğanay B., Aytemir K., Karçaaltıncaba M.
JOURNAL OF DIABETES, vol.7, no.2, pp.279-286, 2015 (SCI-Expanded)
- CVIII. **Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B**
Karatayli S. C., Bozdayi M., Karatayli E., ÖZTÜRK T., Husseini A. A., ALBAYRAK DELİALİOĞLU R., Ozkan M., KALAYLIOĞLU AKYILDIZ Z. I., YALÇIN K., ÇINAR K., et al.
LIVER INTERNATIONAL, vol.35, no.3, pp.846-853, 2015 (SCI-Expanded)
- CIX. **Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir**
Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Buti M., Gouliis J., Arends P., Sypsa V., Manolakopoulos S., Mangia G., Gatselis N., et al.
JOURNAL OF HEPATOLOGY, vol.62, no.2, pp.363-370, 2015 (SCI-Expanded)
- CX. **A potential link between endothelial function, cardiovascular risk, and metabolic syndrome in patients with Non-alcoholic fatty liver disease**
Arslan M. S., Turhan S., Dinçer İ., Mizrak D., Çorapçıoğlu D., İdilman R.
DIABETOLOGY & METABOLIC SYNDROME, vol.6, 2014 (SCI-Expanded)
- CXI. **Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta**
Kabacam G., Wedemeyer H., SAVAŞ B., Keskin O., Dalekos G., TABAK Ö. F., İDİLMAN R., Erhardt A., YALÇIN K., Bozdayi M. A., et al.
LIVER INTERNATIONAL, vol.34, no.8, pp.1207-1215, 2014 (SCI-Expanded)

- CXII. Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: Performance of phylogenetic analysis of the NS5B, E1, and 5' UTR regions in genotyping efficiency**
Alagoz G. K., Karatayli S. C., Karatayli E., Celik E., Keskin O., Dinc B., ÇINAR K., İDİLMAN R., Yurdaydin C., BOZDAYI A. M.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.25, no.4, pp.405-410, 2014 (SCI-Expanded)
- CXIII. Public awareness of hepatitis B infection in Turkey as a model of universal effectiveness in health care policy**
Gurakar M., Malik M., Keskin O., İDİLMAN R.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.25, no.3, pp.304-308, 2014 (SCI-Expanded)
- CXIV. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm**
Razavi H., Waked I., Sarrazin C., Myers R. P., Idilman R., Calinas F., Vogel W., Mendes Correa M. C., Hezode C., Lazaro P., et al.
JOURNAL OF VIRAL HEPATITIS, vol.21, pp.34-59, 2014 (SCI-Expanded)
- CXV. Historical epidemiology of hepatitis C virus (HCV) in selected countries**
Bruggmann P., Berg T., Ovrehus A. L. H., Moreno C., Brandao Mello C. E., Roudot-Thoraval F., Marinho R. T., Sherman M., Ryder S. D., Sperl J., et al.
JOURNAL OF VIRAL HEPATITIS, vol.21, pp.5-33, 2014 (SCI-Expanded)
- CXVI. A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control**
Karatayli E., Altunoglu Y. C., Karatayli S. C., Alagoz S. G. K., ÇINAR K., YALÇIN K., İDİLMAN R., Yurdaydin C., BOZDAYI A. M.
JOURNAL OF CLINICAL VIROLOGY, vol.60, no.1, pp.11-15, 2014 (SCI-Expanded)
- CXVII. Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease**
Idilman I. S., Keskin O., ELHAN A. H., Idilman R., KARÇAALTINCABA M.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.49, no.5, pp.617-624, 2014 (SCI-Expanded)
- CXVIII. Strategies to manage hepatitis C virus (HCV) disease burden**
Wedemeyer H., Duberg A. S., Buti M., Rosenberg W. M., Frankova S., Esmat G., Ormeci N., Van Vlierberghe H., Gschwantler M., AKARCA U. S., et al.
JOURNAL OF VIRAL HEPATITIS, vol.21, pp.60-89, 2014 (SCI-Expanded)
- CXIX. Endoscopic treatment of biliary complications following liver transplantation**
Seven G., ÇINAR K., İDİLMAN R., TÜZÜNER A., Hazinedaroglu S. M., Karayalcin S., Bahar K.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.25, no.2, pp.156-161, 2014 (SCI-Expanded)
- CXX. Tumour necrosis factor-alpha, interleukin-10, interferon-gamma and vitamin D receptor gene polymorphisms in patients with chronic hepatitis delta**
Karatayli S. C., Ulger Z. E., Ergul A. A., Keskin O., Karatayli E., Albayrak R., Ozkan M., Idilman R., Yalcin K., Bozkaya H., et al.
JOURNAL OF VIRAL HEPATITIS, vol.21, no.4, pp.297-304, 2014 (SCI-Expanded)
- CXXI. Manometric assessment of esophageal motor function in patients with primary biliary cirrhosis**
Bektaş M., Seven G., İDİLMAN R., Yakut M., DOĞANAY ERDOĞAN B., Kabacam G., Ustun Y., Korkut E., Kalkan C., Sahin G., et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE, vol.25, no.3, pp.230-234, 2014 (SCI-Expanded)
- CXXII. Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naïve patients with chronic hepatitis B**
Keskin O., Ormeci A. C., Baran B., Kabacam G., Tuzun A., Karatayli E., Akyuz F., Karatayli S., BOZDAYI A. M., Onel D., et al.
ANTIVIRAL THERAPY, vol.19, no.6, pp.543-550, 2014 (SCI-Expanded)
- CXXIII. Vanishing bile duct syndrome after allogeneic bone marrow transplantation: Is it the end of the road?**
Bakanay S. M., Ugur Bilgin A., Bektaş M., İDİLMAN R., Erden E., Arat M., ARSLAN Ö.

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.24, no.4, pp.359-362, 2013 (SCI-Expanded)

- CXXIV. **Hepatic Steatosis: Quantification by Proton Density Fat Fraction with MR Imaging versus Liver Biopsy**

İDİLMAN İ. S., Aniktar H., İDİLMAN R., Kabacam G., SAVAŞ B., ELHAN A. H., Celik A., Bahar K., KARÇAALTINCABA M. RADIOLOGY, vol.267, no.3, pp.767-775, 2013 (SCI-Expanded)

- CXXV. **Kidney transplantation from hepatitis B (HB)-positive donors to HB negative recipients: anti-HB Core immunoglobulin G became positive in all recipients after the transplantation.**

Celebi Z. K., Sengul Ş., Soypacaci Z., Yayar O., Idilman R., Tuzuner A., KEVEN K.

Transplantation proceedings, vol.45, no.3, pp.923-5, 2013 (SCI-Expanded)

- CXXVI. **Clonal analysis of the quasispecies of antiviralresistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir**
Karatayli E., İDİLMAN R., Karatayli S. C., Cevik E., Yakut M., Seven G., Kabaçam G., BOZDAYI A. M., Yurdaydin C. Antiviral Therapy, vol.18, no.1, pp.77-85, 2013 (SCI-Expanded)

- CXXVII. **Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactions**

Nishimura T., Hu Y., Wu M., Pham E., Suemizu H., Elazar M., Liu M., İDİLMAN R., Yurdaydin C., Angus P., et al. Journal of Pharmacology and Experimental Therapeutics, vol.344, no.2, pp.388-396, 2013 (SCI-Expanded)

- CXXVIII. **The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country**

Toy M., ÖNDER F. O., İDİLMAN R., Kabacam G., Richardus J. H., Bozdayi M., Akdogan M., Kuloglu Z., KANSU TANCA A., Schalm S., et al.

EUROPEAN JOURNAL OF HEALTH ECONOMICS, vol.13, no.5, pp.663-676, 2012 (SSCI)

- CXXIX. **HBeAg-positive hepatitis delta: Virological patterns and clinical long-term outcome**

Heidrich B., C. Serrano B., İDİLMAN R., Kabaçam G., Bremer B., Raupach R., Önder F. O., Deterding K., Zacher B. J., Taranta A., et al.

Liver International, vol.32, no.9, pp.1415-1425, 2012 (SCI-Expanded)

- CXXX. **Entecavir treatment of chronic hepatitis D**

Kabaçam G., Önder F. O., Yakut M., Seven G., Karatayli S. C., Karatayli E., SAVAŞ B., İDİLMAN R., BOZDAYI A. M., Yurdaydin C.

Clinical Infectious Diseases, vol.55, no.5, pp.645-650, 2012 (SCI-Expanded)

- CXXXI. **Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients**

Idilman R., Cinar K., Seven G., Bozkus Y., ELHAN A. H., Bozdayi M., Yurdaydin C., Bahar K.

JOURNAL OF VIRAL HEPATITIS, vol.19, no.3, pp.220-226, 2012 (SCI-Expanded)

- CXXXII. **Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS**

Karatayli S. C., Alagöz S. G., Mizrak D., Sayki M., Özkan M., SAVAŞ B., Erden E., ÇINAR K., İDİLMAN R., Yurdaydin C., et al.

Turkish Journal of Gastroenterology, vol.23, no.1, pp.46-53, 2012 (SCI-Expanded)

- CXXXIII. **Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection**

Karatayli E., Karatayli S. C., ÇINAR K., GÖKAHMETOĞLU S., GÜVEN K., İDİLMAN R., Yurdaydin C., BOZDAYI A. M.

Journal of Clinical Virology, vol.53, no.2, pp.130-134, 2012 (SCI-Expanded)

- CXXXIV. **Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin**

Seven G., ÇINAR K., Yakut M., İDİLMAN R., Özden A.

Turkish Journal of Gastroenterology, vol.22, no.6, pp.582-586, 2011 (SCI-Expanded)

- CXXXV. **Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients**

Celik I., Karatayli E., Çevik E., Gökcé Kabakçı S., Karatayli S. C., Dinç B., ÇINAR K., Yalçın K., İDİLMAN R., Yurdaydin C., et al.

Archives of Virology, vol.156, no.12, pp.2215-2220, 2011 (SCI-Expanded)

- CXXXVI. **Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: Before and after transplantation**
İDİLMAN R., Arat M.
Expert Review of Anti-Infective Therapy, vol.9, no.8, pp.641-652, 2011 (SCI-Expanded)
- CXXXVII. **Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C**
Çoban Ş., İDİLMAN R., Erden E., Tužur A.
Hepato-Gastroenterology, vol.58, no.109, pp.1301-1306, 2011 (SCI-Expanded)
- CXXXVIII. **Lymphoproliferative Disorders in Individuals With Chronic Hepatitis B and C in the Turkish Population**
İDİLMAN R., Bozkus Y., CENGİZ SEVAL G., Mizrak D., ÇINAR K., Ustun Y., Bektas M., Arat M., AKBULUT H., DOĞANAY ERDOĞAN B., et al.
JOURNAL OF MEDICAL VIROLOGY, vol.83, no.6, pp.974-980, 2011 (SCI-Expanded)
- CXXXIX. **Natural history and treatment of chronic delta hepatitis.**
Yurdaydin C., Idilman R., Bozkaya H., Bozdayi A.
Journal of viral hepatitis, vol.17, no.11, pp.749-56, 2010 (SCI-Expanded)
- CXL. **MR angiography of esophageal mural veins in portal hypertension: a correlation with endoscopic grades of esophageal varices.**
Erden A., İDİLMAN R., Erden I., Bektaş M., Özden A.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.21, no.3, pp.275-9, 2010 (SCI-Expanded)
- CXLI. **The Characteristics and Clinical Outcome of Drug-induced Liver Injury A Single-center Experience**
İDİLMAN R., Bektas M., Cinar K., TÖRÜNER M., Cerit E. T., DOĞANAY ERDOĞAN B., Erden E., Bozkaya H., Bahar K., Karayalcin S., et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY, vol.44, no.6, 2010 (SCI-Expanded)
- CXLII. **Endoscopic management of biliary parasitic diseases**
Bektaş M., Dökmeci A., ÇINAR K., Halici I., Oztas E., Karayalcin S., İDİLMAN R., Sarioglu M., Ustun Y., Nazligul Y., et al.
Digestive Diseases and Sciences, vol.55, no.5, pp.1472-1478, 2010 (SCI-Expanded)
- CXLIII. **Gastric aberrant pancreas**
Mizrak D., Bektaş M., KAYGUSUZ G., ÇINAR K., İDİLMAN R., Özden A.
Turkish Journal of Gastroenterology, vol.21, no.1, pp.68-69, 2010 (SCI-Expanded)
- CXLIV. **Aflatoxin exposure in viral hepatitis patients in Turkey**
Mizrak D., Engin B., ÖNDER F. O., Yener B., Bektas M., Biyikli Z., İDİLMAN R., ÇINAR K., Karayalcin K., Ersoz S., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.20, no.3, pp.192-197, 2009 (SCI-Expanded)
- CXLV. **A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients**
İDİLMAN R., Kaymakoglu S., Oguz Onder F., Ahishali E., Bektas M., ÇINAR K., Pinarbasi B., Karayalcin S., Badur S., Cakaloglu Y., et al.
Journal of Viral Hepatitis, vol.16, no.4, pp.279-285, 2009 (SCI-Expanded)
- CXLVI. **Veins around the esophagus and the stomach: Do their calibrations provide a diagnostic clue for portal hypertensive gastropathy?**
Erden A., İDİLMAN R., Erden I., Ozden A.
CLINICAL IMAGING, vol.33, no.1, pp.22-24, 2009 (SCI-Expanded)
- CXLVII. **PPAR-alpha L162V polymorphism in human hepatocellular carcinoma**
Koytak E. S., Mizrak D., Bektas M., Verdi H., ARSLAN ERGÜL A., Idilman R., Cinar K., Yurdaydin C., Ersoez S., Karayalcin K., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.19, no.4, pp.245-249, 2008 (SCI-Expanded)
- CXLVIII. **Hepatic complications of allogeneic hematopoietic cell transplantation**
İDİLMAN R., Arat M.
Turkish Journal of Hematology, vol.25, no.3, pp.111-123, 2008 (SCI-Expanded)
- CXLIX. **Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals**

- with non-alcoholic steatohepatitis**
 Idilman R., Mizrak D., Corapcioglu D., Bektas M., Doganay B., Sayki M., Coban S., Erden E., Soykan I., Emral R., et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.28, no.2, pp.200-208, 2008 (SCI-Expanded)
- CL. Adjuvant therapeutic plasma exchange in liver failure - Assessments of clinical and laboratory parameters**
 Bektas M., İDİLMAN R., Soykan I., Soydan E., Arat M., ÇINAR K., Coban S., Tuzun A., Bozkaya H., Ormeci N., et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY, vol.42, no.5, pp.517-521, 2008 (SCI-Expanded)
- CLI. P wave dispersion is prolonged in patients with Wilson's disease**
 Arat N., Kacar S., Golbasi Z., Akdogan M., Sokmen Y., Kuran S., İDİL MAN R.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.14, no.8, pp.1252-1256, 2008 (SCI-Expanded)
- CLII. Hydatid cysts in muscle: a modified percutaneous treatment approach**
 Ormeci N., Idilman R., Akyar S., Palabiyikoglu M., Coban S., Erdem H., Ekiz F.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, vol.11, no.3, pp.204-208, 2007 (SCI-Expanded)
- CLIII. The fate of recipient-derived hepatocytes in sex-mismatched liver allograft following liver transplantation**
 Idilman R., Erden E., KUZU I., Ersoz S., Karayalcin S.
CLINICAL TRANSPLANTATION, vol.21, no.2, pp.202-206, 2007 (SCI-Expanded)
- CLIV. A case of systemic lupus erythematosus presenting with protein-losing enteropathy**
 Türkçapar N., ÖZYÜNCÜ N., ÇINAR K., ENSARI A., KÜÇÜK N. Ö., İDİL MAN R., Duman N., Özden A.
Turkish Journal of Gastroenterology, vol.17, no.3, pp.226-230, 2006 (SCI-Expanded)
- CLV. Antituberculous therapy-induced fulminant hepatic failure: Successful treatment with liver transplantation and nonstandard antituberculous therapy**
 Idilman R., Ersoz S., Coban S., Kumbasar Z., Bozkaya H.
LIVER TRANSPLANTATION, vol.12, no.9, pp.1427-1430, 2006 (SCI-Expanded)
- CLVI. Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy**
 Idilman R.
GUT, vol.55, no.8, pp.1208-1209, 2006 (SCI-Expanded)
- CLVII. Macro-amylasemia in a patient with selective IgA deficiency and antiphospholipid antibodies**
 Türkçapar N., ÖZYÜNCÜ N., İDİL MAN R., ENSARI A., Soylu K., Özden A.
Turkish Journal of Gastroenterology, vol.17, no.2, pp.140-143, 2006 (SCI-Expanded)
- CLVIII. Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment**
 Uzun Y., Bozkaya H., Erden E., Cinar K., Idilman R., Yurdaydin C., Uzunalimoglu O.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol.21, no.6, pp.977-981, 2006 (SCI-Expanded)
- CLIX. Long-term prognosis of nonalcoholic fatty liver disease: Is pharmacological therapy actually necessary?**
 Cinar K., Coban S., Idilman R., Tuzun A., Sarioglu M., Bektas M., Erden E., Bozkaya H., Ozden A.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol.21, no.1, pp.169-173, 2006 (SCI-Expanded)
- CLX. Evaluation of the effect of transplant-related factors and tissue injury on donor-derived hepatocyte and gastrointestinal epithelial cell repopulation following hematopoietic cell transplantation**
 Idilman R., KUZU I., Erden E., Arat M., Soydan E., Soykan I., Akyol G., Karayalcin S., Akan H., BEKSAÇ M.
BONE MARROW TRANSPLANTATION, vol.37, no.2, pp.199-206, 2006 (SCI-Expanded)
- CLXI. Intestinal B cell lymphoma associated with chronic hepatitis C and celiac disease**
 Coban S., Palabiyikoglu M., ENSARI A., Idilman R., Koklu S., Yolcu O., Ormeci N.
DIGESTIVE DISEASES AND SCIENCES, vol.50, no.12, pp.2359-2361, 2005 (SCI-Expanded)
- CLXII. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver**
 Arat M., Idilman R., Soydan E., Soykan I., Erden E., Karayalcin S., Akan H.
CLINICAL TRANSPLANTATION, vol.19, no.6, pp.798-803, 2005 (SCI-Expanded)
- CLXIII. Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis**
 Verdi H., Koytak E., Onder O., Cinar K., Idilman R., Erden E., Bozdayi A., Yurdaydin M., Uzunalimoglu D., Bozkaya H.

- JOURNAL OF INVESTIGATIVE MEDICINE, vol.53, no.7, pp.353-359, 2005 (SCI-Expanded)
- CLXIV. **Trefoil factor expression graft-versus-host disease of in biliary epithelium of the liver after allogeneic hematopoietic cell transplantation**
Idilman R., Erden E., Arat M., Soydan E., Erkan O., KUZU I., Sahin Y., Coban S., Bozdayi M., Giraud A., et al.
TRANSPLANTATION, vol.80, no.8, pp.1099-1104, 2005 (SCI-Expanded)
- CLXV. **A new percutaneous approach for the treatment of hydatid cyst of the kidney: Long-term follow-up**
Ormeci N., Idilman R., Tuzun A., Erdem H., Palabiyikoglu M.
INTERNATIONAL UROLOGY AND NEPHROLOGY, vol.37, no.3, pp.461-464, 2005 (SCI-Expanded)
- CLXVI. **Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from Turkish patients with chronic HBV infection**
Bozdayi G., Turkyilmaz A., Idilman R., Karatayli E., Rota S., Yurdaydin C., Bozdayi A.
JOURNAL OF MEDICAL VIROLOGY, vol.76, no.4, pp.476-481, 2005 (SCI-Expanded)
- CLXVII. **Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy**
Idilman R.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol.55, no.6, pp.828-831, 2005 (SCI-Expanded)
- CLXVIII. **An unusual presentation of helicobacter pylori infection: So-called "Russell body gastritis"**
ENSARI A., Savas B., Heper A., KUZU I., Idilman R.
Virchows Archiv, vol.446, no.4, pp.463-466, 2005 (SCI-Expanded)
- CLXIX. **Sexual dysfunctions in HCV patients and its correlations with psychological and biological variables**
Soykan A., Boztas H., Idilman R., Ozel E. T., Tuzun A., Ozden A., KUMBASAR H.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, vol.17, no.2, pp.175-179, 2005 (SCI-Expanded)
- CLXX. **Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia**
Bozkaya H., Yurdaydin C., Idilman R., Tuzun A., Cinar K., Erkan O., Bozdayi A., Erden E., Uzun Y., Cetinkaya H., et al.
ANTIVIRAL THERAPY, vol.10, no.2, pp.319-325, 2005 (SCI-Expanded)
- CLXXI. **Recipient-derived hepatocytes in sex-mismatched liver allografts after liver transplantation: Early versus late transplant biopsies**
Idilman R., Erden E., KUZU I., Ersoz S., KARASU A. Z., Karayalcin K., Yuce G., Tokat Y., Sahin Y., Tukun A., et al.
TRANSPLANTATION, vol.78, no.11, pp.1647-1652, 2004 (SCI-Expanded)
- CLXXII. **Lymphoproliferative disorders in chronic hepatitis C**
Idilman R., Colantoni A., De Maria N., Alkan S., Nand S., Van Thiel D.
JOURNAL OF VIRAL HEPATITIS, vol.11, no.4, pp.302-309, 2004 (SCI-Expanded)
- CLXXIII. **Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies**
Idilman R., Arat M., Soydan E., TÖRÜNER M., Soykan I., Akbulut H., Arslan O., Ozcan M., Turkyilmaz A., Bozdayi M., et al.
JOURNAL OF VIRAL HEPATITIS, vol.11, no.2, pp.141-147, 2004 (SCI-Expanded)
- CLXXIV. **Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation.**
Idilman R., Ustun C., Karayaicin S., Aktemel A., Turkyilmaz A., Ozcan M., Arslan O., Bozdayi A., Van Thiel D., Akan H.
Clinical transplantation, vol.17, no.5, pp.438-43, 2003 (SCI-Expanded)
- CLXXV. **Hepatic apoptosis and proliferation in male and female rats fed alcohol: role of cytokines**
Colantoni A., Idilman R., De Maria N., La Paglia N., Belmonte J., Wezeman F., Emanuele N., Van Thiel D., Kovacs E., Emanuele M.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, vol.27, no.7, pp.1184-1189, 2003 (SCI-Expanded)
- CLXXVI. **Reversal of iron deficiency anemia in a patient with gastric antral vascular ectasia treated with cyproheptadine**
Soykan I., TÖRÜNER M., Idilman R., Ozden A.
JOURNAL OF CLINICAL GASTROENTEROLOGY, vol.36, no.2, pp.183-184, 2003 (SCI-Expanded)
- CLXXVII. **Impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals**

- Idilman R., Colantoni A., De Maria N., Ustun C., Sam R., Ing T., Akan H., Koc H., Van Thiel D.
HEPATO-GASTROENTEROLOGY, vol.50, no.49, pp.217-221, 2003 (SCI-Expanded)
- CLXXVIII. **A new therapeutic approach for treatment of hydatid cysts of the spleen**
Ormeci N., Soykan I., Palabiyikoglu M., Idilman R., Erdem H., Bektas A., Sarioglu M.
DIGESTIVE DISEASES AND SCIENCES, vol.47, no.9, pp.2037-2044, 2002 (SCI-Expanded)
- CLXXIX. **Is pain experienced during liver biopsy an important factor?**
Soykan I., TÖRÜNER M., Sarioglu M., Idilman R.
JOURNAL OF CLINICAL GASTROENTEROLOGY, vol.35, no.1, pp.102-103, 2002 (SCI-Expanded)
- CLXXX. **Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C.**
De Maria N., Colantoni A., Idilman R., Friedlander L., Harig J., Van Thiel D. H.
Hepato-gastroenterology, vol.49, no.45, pp.788-92, 2002 (SCI-Expanded)
- CLXXXI. **Estrogen status and response to combination therapy for chronic hepatitis C**
De Maria N., Colantoni A., Idilman R., Leone N., Villa E., Van Thiel D.
JOURNAL OF HEPATOLOGY, vol.36, pp.233, 2002 (SCI-Expanded)
- CLXXXII. **The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C**
Idilman R., De Maria N., Colantoni A., Nadir A., Van Thiel D.
AMERICAN JOURNAL OF GASTROENTEROLOGY, vol.97, no.2, pp.435-439, 2002 (SCI-Expanded)
- CLXXXIII. **Liver transplantation for fulminant hepatic failure**
Van Thiel D., Brems J., Nadir A., Idilman R., Colantoni A., Holt D., Edelstein S.
JOURNAL OF GASTROENTEROLOGY, vol.37, pp.78-81, 2002 (SCI-Expanded)
- CLXXXIV. **Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C**
Idilman R., Cetinkaya H., Savas I., Aslan N., SAK S., Bastemir M., Sarioglu M., Soykan I., Bozdayi M., Colantoni A., et al.
JOURNAL OF MEDICAL VIROLOGY, vol.66, no.1, pp.34-39, 2002 (SCI-Expanded)
- CLXXXV. **Repopulation of liver endothelial cells, but not hepatocytes, by allogeneic hematopoietic cell transplants.**
Idilman R., Tukun A., Erdem E., Arat M., TÖRÜNER M., Soykan I., KUZU I., Ozcan M., Topcuoglu P., Soydan E., et al.
BLOOD, vol.98, no.11, 2001 (SCI-Expanded)
- CLXXXVI. **B-cell lymphoproliferative and plasma cell disorders in individuals with chronic hepatitis C.**
Idilman R., Colantoni A., De Maria N., Alkan S., Nand S., Soykan I., TÖRÜNER M., Ozden A., Dokmeci A., Van Thiel D.
HEPATOLOGY, vol.34, no.4, 2001 (SCI-Expanded)
- CLXXXVII. **Increased effective immunogenicity to high-dose and short-interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis**
De Maria N., Idilman R., Colantoni A., Van Thiel D.
JOURNAL OF VIRAL HEPATITIS, vol.8, no.5, pp.372-376, 2001 (SCI-Expanded)
- CLXXXVIII. **Evidence of oxidative injury during aging of the liver in a mouse model.**
Colantoni A., Idilman R., de Maria N., Duffner L., Van Thiel D., Witte P., Kovacs E.
JOURNAL OF THE AMERICAN AGING ASSOCIATION, vol.24, no.2, pp.51-57, 2001 (SCI-Expanded)
- CLXXXIX. **Effect of human immunodeficiency virus on the outcome of hepatitis C virus infection**
Idilman R., Colantoni A., De Maria N.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.36, no.3, pp.225-234, 2001 (SCI-Expanded)
- CXC. **The impact of previous HBV infection on the course of chronic hepatitis C**
De Maria N., Colantoni A., Friedlander L., Leandro G., Idilman R., Harig J., Van Thiel D.
AMERICAN JOURNAL OF GASTROENTEROLOGY, vol.95, no.12, pp.3529-3536, 2000 (SCI-Expanded)
- CXCI. **Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation: Risk and benefit ratio of HBV vaccination in recipients.**
Idilman R., Ustun C., Akan H., Karayalcin S., Ozcan M., Arslan O., Ilhan O., Akyol G., Bozdayi M., Colantoni A., et al.
HEPATOLOGY, vol.32, no.4, 2000 (SCI-Expanded)
- CXCII. **Influence of sex hormonal status on alcohol-induced oxidative injury in male and female rat liver.**
Colantoni A., La Paglia N., De Maria N., Emanuele M. A., Emanuele N. V., Idilman R., Harig J., Van Thiel D. H.
Alcoholism, clinical and experimental research, vol.24, no.9, pp.1467-73, 2000 (SCI-Expanded)
- CXCIII. **Antibody response to hepatitis B virus vaccination in individuals with hepatitis C virus infection**

- De Maria N., Idilman R., Colantoni A., Harig J., Van Thiel D.
HEPATOLOGY, vol.32, no.2, pp.444, 2000 (SCI-Expanded)
- CXCIV. **The incidence of Hepatitis G virus in patients with hematological malignancies: The relationship to the number of blood and blood products transfusions**
İDİLMAN R., Ustun C., Aslan O., ÖZCAN M. E., Arat M., Bozkaya H., Bozdayi M., Sengezer T., Uzunalimoglu O., Dokmeci A., et al.
Turkish Journal of Haematology, vol.17, no.2, pp.67-71, 2000 (SCI-Expanded)
- CXCV. **The response to interferon plus ribavirin re-treatment for chronic hepatitis C in interferon non-responders is not influenced by race**
De Maria N., Colantoni A., Idilman R., Harig J., Van Thiel D.
JOURNAL OF HEPATOLOGY, vol.33, no.6, pp.1028-1029, 2000 (SCI-Expanded)
- CXCVI. **Cirrhosis in Turner's syndrome: Case report and literature review**
Idilman R., De Maria N., Colantoni A., Kugelmas M., Van Thiel D.
European Journal of Gastroenterology and Hepatology, vol.12, no.6, pp.707-709, 2000 (SCI-Expanded)
- CXCVII. **Immunosuppressive therapy-induced hepatotoxicity in patients with aplastic anemia**
Dilek I., İDİLMAH R., Fenkci S., Ustun C., KOÇ H., İLHAN O., Akan H.
Turkish Journal of Haematology, vol.17, no.3, pp.111-117, 2000 (SCI-Expanded)
- CXCVIII. **Adoptive immunity transfer in hepatitis B virus carriers with hematological malignancy who undergoing allogeneic hematopoietic stem cell transplantation**
Idilman R., Ustun C., Turkyilmaz A., GÜRMAN G., Ozcan M., Karayalcin S., Akan H., Ilhan O., BEKSAÇ M., Bozdayi M., et al.
HEPATOLOGY, vol.30, no.4, 1999 (SCI-Expanded)
- CXCIX. **Flow cytometric evaluation of cell counts in bronchoalveolar lavage fluid of patients with hepatitis C virus: As a predictive marker of idiopathic pulmonary fibrosis**
Idilman R., Cetinkaya H., Savas I., Aslan N., Sarioglu M., Bozdayi M., Soykan I., Numanoglu N., Uzunalimoglu O., Dokmeci A.
HEPATOLOGY, vol.30, no.4, 1999 (SCI-Expanded)
- CC. **Hematopoietic stem cell transplantation from non-replicative hepatitis B virus carriers is safe**
Ustun C., Idilman R., GÜRMAN G., Ozcan M., Akyol G., Akan H., Ilhan O., BEKSAÇ M., Uysal A., Konuk N., et al.
JOURNAL OF HEPATOLOGY, vol.31, no.2, pp.202-209, 1999 (SCI-Expanded)
- CCI. **Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma**
BEKSAÇ M., Idilman R.
CANCER, vol.85, no.1, pp.242-243, 1999 (SCI-Expanded)
- CCII. **Is there any correlation between transfusion frequency of blood and blood products and blood-borne hepatitis virus transmission?**
Idilman R., Ustun C., Bozkaya H., Bozdayi M., Akan H.
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)
- CCIII. **Bronchoalveolar lavage fluid findings in patients with hepatitis C virus.**
Cetinkaya H., Idilman R., Savas I., Bastemir M., Karacan O., Sarioglu M., Uzunalimoglu O., Dokmeci A., Numanoglu N.
HEPATOLOGY, vol.28, no.4, 1998 (SCI-Expanded)
- CCIV. **Is there any correlation between transfusion frequency of blood and blood products and hepatitis G virus transmission.**
Idilman R., Akan H., Ustun C., Bozkaya H., Bozdayi M., Uzunalimoglu O., Dokmeci A., Koc H.
HEPATOLOGY, vol.28, no.4, 1998 (SCI-Expanded)
- CCV. **Which hematopoietic stem cell transplantation type is safe for patients with hepatitis B virus carriers.**
Ustun C., Idilman R., Ozcan M., Akan H., Karayalcin S., GÜRMAN G., Ilhan O., BEKSAÇ M., Uysal A., Konuk N., et al.
HEPATOLOGY, vol.28, no.4, 1998 (SCI-Expanded)
- CCVI. **Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma**
Idilman R., De Maria N., Colantoni A., Van Thiel D.

- JOURNAL OF VIRAL HEPATITIS, vol.5, no.5, pp.285-299, 1998 (SCI-Expanded)
- CCVII. Liver transplantation for chronic viral liver disease.**
 Colantoni A., Hassanein T., Idilman R., Van Thiel D. H.
Hepato-gastroenterology, vol.45, no.23, pp.1357-63, 1998 (SCI-Expanded)
- CCVIII. Cladribine therapy in chronic lymphoproliferative disorders: Single center experience**
 BEKSAÇ M., İlhan O., Uysal A., Koc H., Idilman R., Arat M., Ustun C., Ozcan M.
BRITISH JOURNAL OF HAEMATOLOGY, vol.102, no.1, pp.244, 1998 (SCI-Expanded)
- CCIX. Immunosuppressive drug-induced leukoencephalopathy in patients with liver transplant**
 Idilman R., De Maria N., Kugelmas M., Colantoni A., Van Thiel D.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.10, no.5, pp.433-436, 1998 (SCI-Expanded)
- CCX. Fulminant hepatitis in aplastic anemia: hepatitis G or ALG?**
 Akan H., Konuk N., Fenkci S., Dilek I., Idilman R., Tuncer S.
BONE MARROW TRANSPLANTATION, vol.21, no.5, pp.533, 1998 (SCI-Expanded)
- CCXI. Current and future therapies for HCV infection: what should the end point for treatment be?**
 Van Thiel D. H., De Maria N., Colantoni A., Idilman R.
Hepato-gastroenterology, vol.45, no.20, pp.308-20, 1998 (SCI-Expanded)
- CCXII. Interferon treatment of HCV positive cirrhotic patients.**
 Idilman R., Colantoni A., De Maria N., Van Thiel D. H.
Hepato-gastroenterology, vol.45, no.20, pp.340-4, 1998 (SCI-Expanded)
- CCXIII. Donor leukocyte infusions for the treatment of leukemia relapse after allogeneic hematopoietic progenitor cell transplantation.**
 GÜRMAN G., Arslan O., Koc H., Dilek I., Ustun C., Ozcan M., Akan H., İlhan O., SUNGUROĞLU A., Konuk N., et al.
BLOOD, vol.90, no.10, pp.4452, 1997 (SCI-Expanded)
- CCXIV. Polymerase chain reaction for the detection of HCV-RNA: cryoglobulinaemia as a cause for false negative results.**
 Colantoni A., De Maria N., Idilman R., Van Thiel D. H.
Italian journal of gastroenterology and hepatology, vol.29, no.3, pp.273-4, 1997 (SCI-Expanded)
- CCXV. Hepatic osteodystrophy: A review**
 Idilman R., DeMaria N., Uzunalimoglu O., VanThiel D.
HEPATO-GASTROENTEROLOGY, vol.44, no.14, pp.574-581, 1997 (SCI-Expanded)
- CCXVI. Interferon treatment of cirrhotic patients with chronic hepatitis C**
 Idilman R., DeMaria N., Colantoni A., Dokmeci A., VanThiel D.
JOURNAL OF VIRAL HEPATITIS, vol.4, no.2, pp.81-91, 1997 (SCI-Expanded)
- CCXVII. Successful medical treatment of epithelioid hemangioendothelioma of liver**
 Idilman R., Dokmeci A., Beyler A., Bastemir M., Ormeci N., Aras N., Ekinci C., Uzunalimoglu O., DeMaria N., VanThiel D.
ONCOLOGY, vol.54, no.2, pp.171-175, 1997 (SCI-Expanded)
- CCXVIII. Protein C, protein S and antithrombin III levels in nephrotic syndrome.**
 Buyukberber S., Aydogdu I., Buyukberber N., Bektas A., Idilman R., Karatan O., Uysal A.
BLOOD, vol.88, no.10, pp.2982, 1996 (SCI-Expanded)

Articles Published in Other Journals

- I. **Changing trends in the etiology of liver transplantation in Turkiye: A multicenter study**
 Akarsu M., DOLU S., Harputluoglu M., YILMAZ S., Akyildiz M., Gencdal G., Polat K. Y., DİNÇER D., ADANIR H., Turan I., et al.
Hepatology Forum, vol.5, no.1, pp.3-6, 2024 (Scopus)
- II. **TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease**
 YILMAZ Y., ZEYBEL M., ADALI G., COŞAR A., SERTESEN E., SÜMER H., BAHCECİOĞLU I. H., ŞAHİN M., KAYA C., ERGÜN İ., et al.

- Hepatology Forum, vol.4, pp.1-32, 2023 (Scopus)
- III. **The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort**
Yaras S., Demir M., Barutcu S., Yildirim A. E., GÜREL S., Ucbilek E., Kurtulmus I. A., Kayhan M. A., Vatansever S., ADANIR H., et al.
Hepatology Forum, vol.4, no.3, pp.92-96, 2023 (Scopus)
- IV. **Eliminating Viral Hepatitis in Turkey: Achievements and Challenges**
AKARCA U. S., BAYKAM N., GÜNER H. R., GÜNŞAR F., İDİLMAN R., Kaymakoglu S., KÖKSAL I., TABAK Ö. F., YAMAZHAN T.
VIRAL HEPATIT DERGİSİ-VIRAL HEPATITIS JOURNAL, vol.28, no.2, pp.14-21, 2022 (ESCI)
- V. **NSAID-associated drug-induced liver injury prior to and following liver transplantation**
Gumussoy M., GÖKCAN H., BODAKÇI E., KİREMİTCİ S., SAVAŞ B., İDİLMAN R.
HEPATOLOGY FORUM, vol.3, no.3, pp.108-109, 2022 (ESCI)
- VI. **Characteristics of patients with hepatocellular carcinoma: A multicenter study**
Guzelbulut F., KARAOĞULLARINDAN Ü., AKKIZ H., ALTINTAŞ E., DEMİRTAŞ C. Ö., Bahadir O., KEKLİKKIRAN Ç., YILDIRIM A. E., Gumussoy M., Balci H. R., et al.
HEPATOLOGY FORUM, vol.3, no.3, pp.71-76, 2022 (ESCI)
- VII. **HBV/HDV management after liver transplantation: Review**
Muhammad H., Zaffar D., Tehreem A., Peng-Sheng T., ŞİMŞEK C., GÖKCAN H., Gurakar A., İDİLMAN R.
Journal of Liver Transplantation, 2021 (Peer-Reviewed Journal)
- VIII. **Hepatitis D Infection in Asia: A Perspective From an Endemic Region**
GÖKCAN H., İDİLMAN R.
Clinical Liver Disease, vol.18, no.1, pp.26-29, 2021 (Scopus)
- IX. **Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B**
Papatheodoridis G., Dalekos G. N., İDİLMAN R., Sypsa V., Van Boemmel F., Buti M., Calleja J. L., Gouli J., Manolakopoulos S., Loglio A., et al.
JHEP REPORTS, vol.3, no.3, 2021 (ESCI)
- X. **Clinical significance of concomitant extrahepatic autoimmune disease in patients with autoimmune liver disease**
KARAKAYA M. F., USTA Ş., ÖZTÜRK Y., KALKAN Ç., MELEKOĞLU ELLİK Z., ELHAN A. H., SOYKAN A. İ., İDİLMAN R.
Hepatology Forum, vol.1, no.2, pp.3-6, 2021 (ESCI)
- XI. **Immunoglobulin light chain amyloidosis presenting as Budd-Chiari syndrome**
Ozercan M., Eser I., KİREMİTCİ S., PEYNİRCİOĞLU B., Karayalcin S., İDİLMAN R.
Hepatology Forum, vol.2, no.3, pp.120-121, 2021 (Scopus)
- XII. **ATA Index: A novel score for predicting fibrosis stage in chronic viral hepatitis**
Tugsal H. Y., YÜKSEL S., Kabacam G., Evirgen S., Akan K., AKYÜZ F., GÜLLÜOĞLU M., Erden E., BOZDAYI A. M., ÇINAR K., et al.
HEPATOLOGY FORUM, no.1, pp.12-19, 2021 (ESCI)
- XIII. **The Prevalence of Metabolic Associated Fatty Liver Disease in The Turkish Population: A Multicenter Study**
YILMAZ Y., YILMAZ N., ATEŞ F., KARAKAYA M. F., GÖKCAN H., KAYA E., ADALI G., ÇALIŞKAN KARTAL A., ŞEN İ., AHİSHALI E., et al.
Hepatology forum, vol.2, no.2, pp.37-42, 2021 (ESCI)
- XIV. **Hepatitis D virus and liver transplantation: Indications and outcomes**
Muhammad H., Tehreem A., Hammami M. B., Ting P., Idilman R., Gurakar A.
WORLD JOURNAL OF HEPATOLOGY, vol.13, no.3, pp.291-299, 2021 (ESCI)
- XV. **The natural course of non-alcoholic fatty liver disease**
CENGİZ SEVAL G., KABAÇAM G., YAKUT M., SEVEN G., SAVAŞ B., ELHAN A. H., ÇINAR K., İDİLMAN R.
Hepatology Forum, vol.1, no.1, pp.20-24, 2020 (ESCI)
- XVI. **The role of PNPLA3 (rs738409) cg variant on histological progression of non-alcoholic fatty liver**

- disease**
 İDİLMAN R., ÖZEN KARATAYLI S. C., KABAÇAM G., SAVAŞ B., ELHAN A. H., BOZDAYI A. M.
Hepatology Forum, vol.1, no.3, pp.82-87, 2020 (ESCI)
- XVII. Latest updates on chronic viral hepatitis B**
 İDİLMAN R., Karakaya F.
MARMARA MEDICAL JOURNAL, vol.29, pp.33-37, 2016 (ESCI)
- XVIII. Hepatic encephalopathy**
 Yurdaydin C., İDİLMAN R.
European Gastroenterology and Hepatology Review, vol.7, no.4, pp.268-271, 2012 (Scopus)
- XIX. Awareness of the endoscopist affects detection rate of heterotopic gastric mucosa in esophagus**
 Korkut E., Bektas M., SAVAŞ B., Memmedzade F., Öztas E., Üstün Y., İDİLMAN R., Özdena A.
Indian Journal of Gastroenterology, vol.28, no.2, pp.75-76, 2009 (Scopus)
- XX. Anti-viral prophylaxis in inactive hepatitis B virus carriers with hemato-oncological malignancies who receive chemotherapy**
 İDİLMAN R.
Minerva Gastroenterologica e Dietologica, vol.52, no.1, pp.39-45, 2006 (Scopus)

Books & Book Chapters

- I. **Türkiye Viral Hepatit Önleme ve Kontrol Programı** "Sağlık Bakanlığı Yayın No, Ankara
 AKARCA U. S., AKINCI E., AKYILDIZ M., BAYKAM N., BEŞİŞİK S. F., BODUR H., GÜNSAR F., HÜLAGÜ S., İDİLMAN R., KARASU A. Z., et al.
 Sağlık Bakanlığı yayını Ankara, Ankara, 2018

Refereed Congress / Symposium Publications in Proceedings

- I. **Case series of C282Y mutation in the HFE gene in Turkey: Single-center experience**
 BODAKÇI E., GÖKCAN H., güvener t., YILMAZ V., ER R. E., KARAKAYA M. F., İDİLMAN R.
 19. Euroasian Hepatogastroenterology and Surgery, 13 November 2023
- II. **Familial NAFLD Cirrhosis Case Series**
 AKARCA H. T., GÖKCAN H., GÜVENİR S. T., YILMAZ V., İDİLMAN R.
 19. Euroasian Hepatogastroenterology and Surgery, 13 November 2023
- III. **noninvasive fibrosis markers for assessment for liver fibrosis in patients with chronic hepatitis delta**
 KARAKAYA M. F., KURU ÖZ D., Turan Gökçe D., DUMAN S., Ellik Z. M., GÜMÜŞSOY M., GÜVENİR S. T., YILMAZ V., GÖKCAN H., İDİLMAN R.
 AASLD 2023 congress, 10 November 2023
- IV. **REGIONAL DIFFERENCES IN ACUTE KIDNEY INJURY PREVALENCE, CLINICAL CHARACTERISTICS AND PATIENT OUTCOMES IN A MULTI-NATIONAL CONSORTIUM OF INPATIENTS WITH CIRRHOSIS**
 Wong F., George J., Hayes P. C., Torre A., Kamath P. S., Xie Q., Topazian M., Desalegn H., İDİLMAN R., Alvares-Da-Silva M. R., et al.
 Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023
- V. **GLOBAL PREVALENCE OF INFECTIONS AND IMPACT OF REGIONAL VARIATIONS ON OUTCOMES: MULTI-NATIONAL CONSORTIUM OF CIRRHOSES STUDY**
 Xie Q., Cao Z., Choudhury A. K., Kamath P. S., Topazian M., Hayes P. C., Torre A., Desalegn H., İDİLMAN R., Alvares-Da-Silva M. R., et al.
 Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023
- VI. **PRIVATE INSURANCE ACCESS IS ASSOCIATED WITH HIGHER LIVER TRANSPLANT LISTING AND**

TRANSPLANT ACCESS AND LOWER MORTALITY COMPARED TO NATIONAL INSURANCES IN A LARGE MULTINATIONAL COHORT OF INPATIENTS WITH CIRRHOSIS

Bajaj J. S., Wong F., Xie Q., Kamath P. S., Topazian M., Hayes P. C., Torre A., Desalegn H., İDİLMAN R., Cao Z., et al.
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023

VII. NON - INVASIVE FIBROSIS MARKERS FOR ASSESSMENT OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS DELTA

BODAKÇI E., KARAKAYA M. F., KURU ÖZ D., Gokce D. T., DUMAN S., Ellik Z. M., Gümüşsoy M., GÜVENİR S. T., Yilmaz V., ER R. E., et al.
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023

VIII. A STUDY OF ACUTE LIVER INJURY ASSOCIATED WITH ORNIDAZOLE: ANALYSIS OF 82 CASES IN TURKIYE

TURAN İ., DURMAZER E. N., Vatansever S., Caliskan A. R., Harputluoglu M., Efe C., İDİLMAN R., BODAKÇI E., KARASU A. Z., AKARCA U. S., et al.
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023

IX. ALCOHOL-RELATED ETIOLOGY IS AN INDEPENDENT PREDICTOR OF INPATIENT MORTALITY IN PATIENTS WITH CIRRHOSIS IN A PROSPECTIVE GLOBAL CONSORTIUM

Choudhury A. K., Wong F., Xie Q., Kamath P. S., Topazian M., Hayes P. C., Torre A., Desalegn H., İDİLMAN R., Cao Z., et al.
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023

X. development of Metabolik disorders in Liver transplant recipients

Erdemir G., GÖKCAN H., İDİLMAN R.
The 2023 International congress of ILTS ELITA and LICAGE, 03 May 2023

XI. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.

DUMAN S., KURU ÖZ D., GÜMÜŞSOY M., KİREMİTCİ S., GÖKCAN H., ÖZERCAN A. M., İDİLMAN R.
AASLD-TASL hepatology connect meeting, 28 - 29 April 2023

XII. Natural Disease outcome in patients with NAFLDÇ a study with paired liver biopsies
GÜMÜŞSOY M., TURAN D., ekelik m., KİREMİTCİ S., DUMAN S., GÜVENİR S. T., GÖKCAN H., İDİLMAN R.
AASLD-TASL hepatology connect meeting, 28 April 2023

XIII. effect of prognostic tests on disease outcome of alcohol-related liver disease

zengin b. a., GÜMÜŞSOY M., DUMAN S., BODAKÇI E., ÖZERCAN A. M., ER R. E., KARAKAYA M. F., GÖKCAN H., İDİLMAN R.
AASLD-TASL hepatology connect meeting, 28 April 2023

XIV. Development of Metabolic Disorders in Transplant Recipients

erdemir g., GÖKCAN H., GÜRSOY ÇORUH A., GÜMÜŞSOY M., DUMAN S., İDİLMAN R.
AASLD-TASL hepatology connect meeting, 28 - 29 April 2023

XV. A case of AFP producing cholangiocarcinoma

BODAKÇI E., GÜMÜŞSOY M., GÜVENİR S. T., KARAKAYA F., GÖKCAN H., İDİLMAN R.
AASLD-TASL hepatology connect meeting, 28 - 29 April 2023

XVI. Identification of risk factors for alcohol relapse in liver transplant patients with alcohol- related liver disease.

TURAN D., GÜNŞAR F., harputluoğlu m., KABAÇAM G., GÖKCAN H., AKARSU M., AKYILDIZ M., ADALI G., ARI D., TURAN İ., et al.

EASL Congress 21-24 June 2023, 21 April 2023

XVII. A Combination Of Non-Invasive Tests In Detection Of NAFLD-Related Advanced Fibrosis Is Not Superior To MRE Alone

- Duman S., Gümüşsoy M., Kuru D., Kiremitci S., Gökcen H., Bodakçı E., Melekoğlu Z., Ulaş B., Elhan A. H., Savaş B., et al.
39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber, Bochum, Germany, 27 - 28 January 2023, vol.61, pp.30
- XVIII. **MEFIB AND MAST SCORES ASSESSMENT OF INCIDENT LIVER-RELATED OUTCOMES IN NONALCOHOLIC FATTY LIVER DISEASE: AN INDIVIDUAL PATIENT META-ANALYSIS**
Noureddin N., Ajmera V., Bergstrom J., Huang D., Siddiqi H., Majzoub A. M., Nayfeh T., Tamaki N., Izumi N., Nakajima A., et al.
American Association for the Study of Liver Diseases, The Liver Meeting (AASLD 2022), United States Of America, 4 - 08 November 2022
- XIX. **Alkol Dışı Yağlı Karaciğer Hastalığı Doğal Seyri: Ardışık İkili Karaciğer Biyopsilerinin Karşılaştırılması**
GÜMÜŞSOY M., TURAN D., EKELİK M., KİREMİTCİ S., BODAKÇI E., DUMAN S., MELEKOĞLU ELLİK Z., GÜVENİR S. T., ER R. E., KARAKAYA M. F., et al.
39. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Turkey, 22 November 2022
- XX. **Natural disease Outcome in patients with NAFLD: A study with paired liver biopsy**
GÜMÜŞSOY M., Turan Gökçe D., KİREMİTCİ S., BODAKÇI E., DUMAN S., MELEKOĞLU ELLİK Z., GÜVENİR S. T., ER R. E., KARAKAYA M. F., GÖKCAN H., et al.
aasld 2022, 04 November 2022
- XXI. **Metabolic Syndrome in liver Transplant recipient**
KARA G., GÖKCAN H., İDİLMAN R.
AASLD 2022, 4 - 08 November 2022
- XXII. **Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in patients with hepatitis B virus related cirrhosis**
YAPALI S., GÖKCAN H., DURAK S., MELEKOĞLU ELLİK Z., ADANIR H., GÜNDÜZ F. F., ÖZDİL K., DİNÇER D., İDİLMAN R.
international Liver congress ILC 2022 (EASL), 22 - 26 June 2022
- XXIII. **Effectiveness of MRI methods in the assessment of hepatic steatosis in living liver donors**
KURU ÖZ D., MELEKOĞLU ELLİK Z., GÜRSOY ÇORUH A., GÜMÜŞSOY M., DUMANLI S., ER R. E., BALCI D., GÖKCAN H., İDİLMAN R., ERDEN A.
international Liver congress ILC 2022 (EASL), 22 June 2022
- XXIV. **Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in liver transplant recipients: a multicenter study**
GÖKCAN H., YAPALI S., MELEKOĞLU ELLİK Z., GÖKÇEN P., ADANIR H., DURAK S., ARI D., GÜZELBULUT F., EKMEN N., YILDIRIM A. E., et al.
international Liver congress ILC 2022 (EASL), 22 - 26 June 2022
- XXV. **Preliminary Results of The effectiveness and safety of Tenofovir alafenamide Fumarate Prophylaxis in HBV individuals, who received Chemo/Immunosuppression therapy**
GÜNDÜZ F. F., DURAK S., ÜNSAL Y., DEMİR M., MELEKOĞLU ELLİK Z., YILDIRIM A. E., ADANIR H., DEMİRTAŞ C. Ö., BALABAN H. Y., ÖZER ETİK D., et al.
international Liver congress ILC 2022 (EASL), 22 June 2022
- XXVI. **Trends and causes of etiology in adult liver transplant patients: multicenter study**
AKARSU M., Harputluoğlu M., YILMAZ S., GENÇDAL G., AKYILDIZ M., DİNÇER D., ADANIR H., TURAN İ., GÜNŞAR F., KARASU A. Z., et al.
international Liver congress ILC 2022 (EASL), 22 - 26 June 2022
- XXVII. **Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in liver transplant recipients: A multicenter study**
YAPALI S., GÖKCAN H., MELEKOĞLU ELLİK Z., GÖKÇEN P., ADANIR H., DURAK S., ARI D., GÜZELBULUT F., EKMEN N., ÖZER ETİK D., et al.
ILTS 2022, 04 May 2022
- XXVIII. **Biliary complications and management in liver transplant recipients with duct to duct anastomosis: A single center experience**

- KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., GÜMÜŞSOY M., MELEKOĞLU ELLİK Z., DOĞANAY ERDOĞAN B., GÖKCAN H., et al.
AASLD-TASL Digital Hepatology Meeting, 14 January 2022
- XXIX. **Presentation and outcome of autoimmune hepatitis during pregnancy**
örmeci a., DUMAN S., İSTEMİHAN Z., GÖKCAN H., ÇAVUŞ B., ARSLAN K., GÜMÜŞSOY M., AKYÜZ F., DEMİR K., BEŞİŞİK S. F., et al.
AASLD-TASL digital Hepatology Connect, 14 January 2022
- XXX. **Development of Metabolic Disorders İn Liver Transplant Patients**
KARA G., GÖKCAN H., GÜMÜŞSOY M., DUMAN S., İDİLMAN R.
AASLD-TASL digital Hepatology Connect, 14 January 2022
- XXXI. **Trends and changes of etiology in adult liver transplant patients: mulitcenter study**
AKARSU M., Harputluoğlu M., YILMAZ S., AKYILDIZ M., GENÇDAL G., polat k. y., DİNÇER D., ADANIR H., TURAN İ., GÜNŞAR F., et al.
AASLD-TASL digital Hepatology Connect, 14 January 2022
- XXXII. **Biliary Complications and Management in Liver Transplant Patients with Duct to Duct Anastomosis: Single Center Experience**
KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., GÜMÜŞSOY M., MELEKOĞLU ELLİK Z., ERDOĞAN AKTÜRK B., GÖKCAN H., et al.
AASLD-TASL digital Hepatology Connect, 14 January 2022
- XXXIII. **Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in patiernts with hepatitis B virus related cirrhosis**
YAPALI S., GÖKCAN H., DURAK S., MELEKOĞLU ELLİK Z., VATANSEVER S., ADANIR H., GÜNDÜZ F. F., ÖZDİL K., DİNÇER D., İDİLMAN R.
AASLD-TASL digital Hepatology Connect, 14 April 2022
- XXXIV. **Efficacy and Safety of Tenofovir alafenamide in hepatitis B virus infected patients with chronic hemodialysis and renal transplantation: a preliminary result**
ADANIR H., ÖZER ETİK D., YILDIRIM A. E., YAPALI S., ARI D., GÖKCAN H., KIYICI M., BALABAN H. Y., ÜÇBİLEK E., Harputluoğlu M., et al.
AASLD-TASL digital Hepatology Connect, 14 January 2022
- XXXV. **The Effect of Clinicopathologic findings of Hepatosellüler carcinoma on posttransplant survival: A multicenter kohort from TASL Liver Transplantation special İnterest group**
AKYILDIZ M., GENÇDAL G., İNCE V., Harputluoğlu M., ZEYTÜNLÜ M., KILIÇ M., TURAN İ., GÜNŞAR F., KARASU A. Z., AKARSU M., et al.
AASLD-TASL digital Hepatology Connect, 14 - 16 January 2022
- XXXVI. **'Duct to Duct Anastomozlu' Karaciğer Transplantasyon Hastalarında Biliyer Komplikasyonlar ve Yönetimi: Tek Merkez Deneyimi**
KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., GÜMÜŞSOY M., MELEKOĞLU ELLİK Z., DOĞANAY ERDOĞAN B., DUMLUPINAR E., et al.
38. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Turkey, 16 November 2021
- XXXVII. **Karaciğer Donörlerinin Preoperatif Yağlanması Değerlendirilmesinde MRG Yöntemlerinin Etkinliği**
Kuru Öz D., Melekoğlu Ellik Z., Gürsoy Çoruh A., Adıgüzel M., Gümüşsoy M., Duman S., Er R. E., Kırımkıran E. O., Balci D., Gökcan H., et al.
38. Ulusal Gastroenteroloji Haftası, 2021, Antalya, Turkey, 16 October - 21 November 2021, pp.160-161
- XXXVIII. **The analysis of liver transplant patients with COVID-19 infection: a national cohort**
KABAÇAM G., TURAN İ., KIYICI M., MELEKOĞLU ELLİK Z., dolu S., Dayangaç M., ARI D., Turan Gökcé D., YILDIRIM A. E., GENÇDAL G., et al.
AASLD-TASL digital Hepatology Connect, İstanbul, Turkey, 15 - 16 January 2021, vol.2, pp.24-25
- XXXIX. **Non-alcoholic fatty liver disease and extrahepatic malignancy**
Gümüşsoy M., Turan Gökcé D., Ulaş B. B., Koç Ö., Karataş G., Bodakçı E., Özerçan M., DUMAN S., MELEKOĞLU ELLİK Z., KARAKAYA M. F., et al.
AASLD-TASL digital Hepatology Connect, 15 January 2021

- XL.** **AMAP RISK SCORE PREDICTS HEPATOCELLULAR CARCINOMA DEVELOPMENT IN CHRONIC HEPATITIS PATIENTS: AN INTERNATIONAL COHORT COLLABORATION**
 Fan R., Papatheodoridis G., Sun J., Innes H., Toyoda H., Xie Q., Mo S., Sypsa V., Guha I. N., Kumada T., et al.
 Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72
- XLI.** **MAGNETIC RESONANCE ELASTOGRAPHY AND TRANSIENT ELASTOGRAPHY TO ASSESS HEPATIC STENOSIS AND LIVER FIBROSIS IN THE LIVER TRANSPLANT SETTING**
 Ellik Z. M., İDİLMAN İ. S., Kartal A. C., Balaban Y. H., KARÇAALTINCABA M., İDİLMAN R.
 Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72
- XLII.** **Outcomes following deceased and live donor liver transplantation for the indication of acute liver failure: amulticenter experience**
 TURAN İ., ALADAĞ M., HARPUTLUOĞLU M. M. M., YILMAZ S., GENÇDAL G., POLAT K. Y., ÖZÇAY F., AKARSU M., ÜNEK T., KARASU A. Z., et al.
 The Digital International Liver Congress (EASL) 2020, 27 - 29 August 2020, vol.73, pp.227
- XLIII.** **Diagnostic accuracy of liver stiffness measurement by fibroscan in liver transplant recipients**
 MELEKOĞLU ELLİK Z., ÇALIŞKAN A., DUMAN S., GÜMÜŞSOY M., ÖZERCAN A. M., ER R. E., ELHAN A. H., İDİLMAN R.
 EASL: The Digital International Liver Congress, 27 - 29 August 2020, vol.73, pp.528
- XLIV.** **ASSOCIATION BETWEEN NON-ALCOHOLIC FATTY LIVER DISEASE AND SUBCLINICAL ATHEROSCLEROSIS AND MYOCARDIAL DYSFUNCTION USING MULTIMODALITY IMAGING**
 ULAŞ B. B., ÖZYÜNCÜ N., ÇALIŞKAN KARTAL A., PEKER E., TURAN GÖKÇE D., GÜMÜŞSOY M., ÖZERCAN M., TULUNAY KAYA C., UZUN Ç., ERDEN G. A., et al.
 ANNUAL MEETING OF AASLD / LIVER MEETING, 8 - 12 November 2019
- XLV.** **TREATMENT DISCONTINUATION IN HBEAG-NEGATIVE CHRONIC HEPATITIS B IS A VIABLE OPTION IN NON-CIRRHOTIC GENOTYPE D CHRONIC HEPATITIS B PATIENTS**
 ŞAH ÜNAL F. T., Keskin O., Yurdcu E., Yilmaz Y., KARAKAYA M. F., Kartal A., Bozdayi M., İDİLMAN R., Yurdaydin C.
 Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70
- XLVI.** **SIMILAR RISK OF HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT DURING LONG-TERM ENTECAVIR (ETV) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS**
 Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Sypsa V., van Boemmel F., Buti M., Luis Calleja J., Gouli I., Manolakopoulos S., Loglio A., et al.
 Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70
- XLVII.** **NATURAL HISTORY OF INACTIVE HBsAg CARRIERS: A 10-YEAR PROSPECTIVE FOLLOW-UP STUDY**
 Yurdaydin C., Keskin O., Yurdcu E., Yakut M., Seven G., Kabacan G., ÖNDER F. O., Bektas M., Bozdayi M., İDİLMAN R.
 Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70
- XLVIII.** **ASSOCIATION BETWEEN NON-ALCOHOLIC FATTY LIVER DISEASE AND SUBCLINICAL ATHEROSCLEROSIS AND MYOCARDIAL DYSFUNCTION USING MULTIMODALITY IMAGING**
 Ulas B. B., ÖZYÜNCÜ N., Kartal A. C., PEKER E., Gokce D. T., Gumussoy M., Ozercan M., TULUNAY KAYA C., UZUN Ç., Erden A., et al.
 Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70
- XLIX.** **TÜRKİYE'DE HEPATİT C ELİMİNASYONU YOL HARİTASI ÖNERİLERİ VE ÇALIŞTAY RAPORU**
 AKARCA U. S., AYGEN B., bodur h., GÜNER H. R., İDİLMAN R., KAYMAKOĞLU S., lazarus j., ÖRMECİ N., Razavi H., Robbins S., et al.
 XI.Uluslararası Viral Hepatit Simpozyumu, Turkey, 14 - 16 June 2019
- L.** **ETIOLOGY OF CIRRHOSES CHANGING TRENDS OVER THE YEARS: A SINGLE-CENTER TURKISH EXPERIENCE**

İDİLMAN R., ÇALIŞKAN KARTAL A., AYDOĞAN M., KARAKAYA M. F., KALKAN Ç., ÖNEM S., ÖRÜNCÜ M., ÖRMECİ N., YURDAYDIN S. C., ÖZKAN H.

DDW 2019, 19 - 21 May 2019

LII. **10 YILLIK PROSPEKTİF ÇALIŞMADA DÜŞÜK VİRAL YÜKLÜ HBV TAŞIYICILARI REAKTİVASYONDAN ZİYADE HBSAG KAYBETMEYE YATKINDIR.**

KESKİN O., YAKUT M., YURDCU E., KALKAN Ç., AGAYEVA S., YILMAZ Y., BEKTAŞ M., BOZDAYI A. M., İDİLMAN R., YURDAYDIN S. C.

12. ULUSAL HEPATOLOJİ KONGRESİ, Antalya, Turkey, 1 - 05 May 2019

LIII. **Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study**

Hardtke S., Wedemeyer H., Caruntu F. A., Curescu M., Kendal Y., AKARCA U. S., Yurdcu E., GÜREL S., Zeuzem S., Erhardt A., et al.

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Austria, 10 - 14 April 2019, vol.70

LIII. **Plasma metabolomic changes modulate the impact of Middle Eastern versus Western Diet in an international cirrhosis cohort**

Cox I. J., İDİLMAN R., Fagan A., Turan D., Ajayi L., Karakaya F., Williams R., Gavis E., Atkinson A., Le Guennec A., et al. International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Austria, 10 - 14 April 2019, vol.70

LIV. **Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients**

Papatheodoridis G., Dalekos G., Yurdaydin C., Sypsa V., van Bommel F., Buti M., Calleja Panero J. L., Chi H., Gouli I., Manolakopoulos S., et al.

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Austria, 10 - 14 April 2019, vol.70

LV. **Noninvasive Fibrosis Scores Are Not Useful for Prediction of Response to Treatment in Chronic Delta Hepatitis**

KESKİN O., YURDCU E., KALKAN Ç., ÇALIŞKAN KARTAL A., ELLİK Z., BOZDAYI A. M., İDİLMAN R., YURDAYDIN S. C. AASLD LIVER MEETING 2018, San-Francisco, Costa Rica, 9 - 13 November 2018

LVI. **Prediction and need for surveillance of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir or tenofovir disoproxil fumarate therapy in Caucasian chronic hepatitis B patients of the PAGE-B Cohort.**

Papatheodoridis G., Dalekos G., YURTAYDIN S. C., Sypsa V., Bommel V., Buti m., Calleja J., Chi H., Gouli I., Mano S., et al.

AASLD, 9 - 13 November 2018

LVII. **Prediction and Need for Surveillance of Hepatocellular Carcinoma (HCC) Development after the First 5 Years of Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF) Therapy in Caucasian Chronic Hepatitis B (CHB) Patients of the PAGE-B Cohort**

Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Sypsa V., van Bommel F., Buti M., Calleja J. L., Chi H., Gouli I., Manolakopoulos S., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Costa Rica, 9 - 13 November 2018, vol.68

LVIII. **Noninvasive Fibrosis Scores Are Not Useful for Prediction of Response to Treatment in Chronic Delta Hepatitis**

Keskin O., Yurdcu E., Kalkan C., Kartal A., Ellik Z., Bozdayi M., İDİLMAN R., Yurdaydin C., Keskin O.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Costa Rica, 9 - 13 November 2018, vol.68

LIX. **ALT Levels and Risk of Hepatocellular Carcinoma (HCC) in Caucasian Chronic Hepatitis B (CHB) Patients Under Long-Term Therapy with Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF)**

Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Sypsa V., van Bommel F., Buti M., Luis Calleja J., Chi H., Gouli I., Manolakopoulos S., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Costa Rica, 9 - 13 November 2018, vol.68

LX. **Patient Selection and Preparation for Liver Transplantation**

İDİLMAN R.

APASL Single Topic Non-Responders, 27 - 29 September 2018

LXI. **Real world data on safety and efficacy of Ledipasvir Sofosbuvir ± RBV, Ombitasvir / Paritaprevir / Ritonavir ± Dasabuvir ± RBV combination therapy for chronic hepatitis C. A Turkey experience.**

DEMİR M., DANIŞ N., KANİ H. T., YILDIRIM A. E., BALKAN A., DEĞERTEKİN M. B., YAPALI S., GÜZELBULUT F., DEMİRCAN M., SOYLU A., et al.

APASL Single Topic Conference, İstanbul, Turkey, 27 - 29 September 2018

LXII. **HEPATİT C ENFEKSİYONUNA BAĞLI DEKOMPANZE SİROZ HASTALARINDA VE KRONİK HEPATİT C ENFEKSİYONU NEDENİYLE KARACİĞER NAKLİ OLANLarda LEDİPASVİR/SOFOSBUVİR TEDAVİSİNİN ETKİLİLİĞİ: TÜRKİYE ERKEN ERİŞİM PROGRAMI SONUÇLARI**

İDİLMAN R., DEMİR M., ALADAĞ M., KAYMAKOĞLU S., EROL C., ÇAVUŞ B., RAİM İ., AKARCA U. S., KÖKLÜ S., ÇAKALOĞLU Y., et al.

34. ULUSAL GASTROENTEROLOJİ HAFTASI, Turkey, 1 - 06 December 2017

LXIII. **OTOIMMÜN KARACİĞER HASTALIKLARINA EŞLİK EDENEKSTRAHEPATİK OTOIMMÜN HASTALIKLAR VE HASTALIK SEYRI ÜZERİNE ETKİSİ**

KARAKAYA M. F., ÖZTEKİN Ş., ÖZTÜRK UÇAR Y., KALKAN Ç., ELHAN A. H., SOYKAN A. İ., İDİLMAN R.

UGH 2017, Turkey, 1 - 06 December 2017

LXIV. **New therapies for HCV**

İDİLMAN R.

16th International Euroasian Congress of Gastroenterology and Surgery, 27 - 30 April 2017

LXV. **Efficacy of ledipasvir and sofosbuvir with/without ribavirin for treatment of chronic hepatitis C patients with advanced liver disease results of a multicenter turkish early access program**

İDİLMAN R., demir m., ALADAĞ M., KAYMAKOĞLU S., EROL C., cavus b., İLİAZ R., AKARCA U. S., köklü s., çakaloğlu y., et al.

Viral Hepatitis, 3 - 04 March 2017

LXVI. **EFFICIACY OF LEDİPASVİR AND SOFOSBUVİR WITH/WITHOUT TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH ADVANCED LIVER DISEASE RESULT OF A MULTICENTER TURKISH EARLY ACCES PROGRAM**

İDİLMAN R., DEMİR M., ALADAĞ M., KAYMAKOĞLU S., EROL C., ÇAVUŞ B., İLİAZ R., AKARCA U. S., SEYFETTİN K., ÇAKALOĞLU Y., et al.

VIRAL HEPATITIS (ENDORSED BY AASLD), 3 - 04 March 2017

LXVII. **Efficacy of ledipasvir and sofosbuvir with/without ribavirin for treatmentof hepatitis C patients Results of a multicenter Turkish Early Access Program**

İDİLMAN R., DEMİR M., ALADAĞ M., KAYMAKOĞLU S., CİHAN E., ÇAVUŞ B., İLLİAZ R., AKARCA U. S., KÖKLÜ S., ÇAKALOĞLU Y., et al.

Viral Hepatitis, 3 - 04 March 2017

LXVIII. **Hepatocellular carcinoma (HCC) is the only factor affecting the excellent survival of Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy**

Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., van Boemmel F., Buti M., Sypsa V., Goulis J., Calleja J. L., Chi H., Manolakopoulos S., et al.

67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64

LXIX. **The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients**

Papatheodoridis G. V., Yurdaydin C., Dalekos G. N., Buti M., Chi H., van Boemmel F., Calleja J. L., Sypsa V., Goulis I., Manolakopoulos S., et al.

67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United

- States Of America, 11 - 15 November 2016, vol.64
- LXX. **The Role Of Genetic Variability Of PNPLA3 (rs738409) On Predisposition To Non-Alcoholic Fatty Liver Disease In Lean Patients**
İDİLMAN R., Karatayli S. C., Karakaya F., Keskin O., Gozukara B., SAVAŞ B., Bozdayi M., ELHAN A. H., Yurdaydin C.
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64
- LXXI. **The Prenylation Inhibitor Lonafarnib Can Induce Post-Treatment Alt Flares With Viral Clearance In Patients With Chronic Delta Hepatitis**
Yurdaydin C., İDİLMAN R., Kalkan C., Karakaya F., Kartal A. C., Keskin O., Karatayli E., Karatayli S. C., BOZDAYI A. M., Koh C., et al.
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64
- LXXII. **High incidence of significant liver fibrosis among HBeAg-positive patients with low levels of ALT**
Sonneveld M. J., Brouwer W. P., Xie Q., Hansen B. E., TABAK Ö. F., İDİLMAN R., de Knegt R. J., Janssen H. L.
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64
- LXXIII. **Chronic hepatitis D is a greater risk factor for hepatocellular carcinoma development than chronic hepatitis B**
Keskin O., Karakaya F., Kalkon C., Kartal A. C., İDİLMAN R., Yurdaydin C.
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64
- LXXIV. **Exploring Optimal Dosing Of Lonafarnib With Ritonavir For The Treatment Of Chronic Delta Hepatitis-Interim Results From The Lowr HdV-2 Study**
Yurdaydin C., İDİLMAN R., Kalkan C., Karakaya F., Kartal A. C., Keskin O., Karatayli E., Karatayli S. C., BOZDAYI A. M., Koh C., et al.
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64
- LXXV. **Hepatoselüler Kanserde Tedavi Yaklaşımı**
İDİLMAN R.
Hepatoloji Okulu 2016, Turkey, 13 - 15 May 2016
- LXXVI. **Hepatitis delta virus kinetics under the prenylation inhibitor lonafarnib suggest HDV metiadted suppression of HBV replication**
YURTAYDIN S. C., Borochov N., KALKAN Ç., BedRoy S., KARATAYLI E., HaynesWilliams V., ÖZEN KARATAYLI S. C., Canini L., Uprichard S., BOZDAYI A. M., et al.
51th Annual Meeting of the European Association for the Study of the Liver (EASL), 13 - 17 April 2016
- LXXVII. **Hepatitis B (HBV) Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Lenalidomide Containing Regimens: A Single Center Experience**
Ataca P., Atilla E., Kircali E., İDİLMAN R., BEKSAÇ M.
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126
- LXXVIII. **Decreasing risk of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients**
Papatheodoridis G. V., İDİLMAN R., Dalekos G. N., Buti M., Chi H., van Boemmel F., Luis Calleja J., Sypsa V., Goulis I., Manolakopoulos S., et al.
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62
- LXXIX. **"Normal" Serum ALT/AST Level in Turkish Population**
KARASU A. Z., Tozun N., İDİLMAN R., Ozdogan O. C., Kaymakoglu S., Cakaloglu Y., AKARCA U. S.
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62
- LXXX. **Prolongation of interferon therapy increases maintained virological response rates and improves**

the natural course of chronic delta hepatitis

Keskin O., Tuzun A., Karakaya F., Kalkan C., Kartal A. C., Karatayli E., Karatayli S. C., BOZDAYI A. M., İDİLMAN R., Yurdaydin C.

66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62

- LXXXI. **Hepatitis C Seropositivity is not as high as Western Countries in the Population Born Between 1945-1965 According to Turkey Nationwide Hepatitis Prevalence Study (TURKHEP 2010)**

Ozdogan O. C., Tozun N., Kaymakoglu S., İDİLMAN R., KARASU A. Z., AKARCA U. S.

66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62

- LXXXII. **Vena caval replacement with cadaveric caval graft for living donor liver transplantation in Budd Chiari syndrome associated with hydatid cyst surgery**

BALCI D., KIRIMKER E. O., DURDU M. S., HAZİNEDAROĞLU S. M., MEÇO B. C., ÖZÇELİK M., YILMAZ A. A., AKAR A. R., KALKAN Ç., İDİLMAN R., et al.

ILTS 21st International Congress, 8 - 11 July 2015

- LXXXIII. **Multiple Genetic Mutations Increasing Thrombotic Risk Predisposing Both Donor and Recipient Thrombotic Complications After Living Donor Liver Transplantation A Case Report**

BALCI D., KIRIMKER E. O., konca c., HAZİNEDAROĞLU S. M., ÖZÇELİK M., MEÇO B. C., YILMAZ A. A., UZUN Ç., KALKAN Ç., İDİLMAN R., et al.

21th ILTS International Congress, 8 - 10 July 2015

- LXXXIV. **Multiple Genetic Mutations Increasing Thrombotic Risk Predisposing Both Donor and Recipient Thrombotic Complications After Living Donor Liver Transplantation: A Case Report**

BALCI D., Kirimker O., KONCA C., HAZİNEDAROĞLU S. M., ÖZÇELİK M., MEÇO B. C., Yilmaz A. A., UZUN Ç., Kalkan C., İDİLMAN R., et al.

21st Annual International Congress of the International-Liver-Transplant-Society (ILTS), Illinois, United States Of America, 8 - 11 July 2015, vol.99, pp.278

- LXXXV. **Vena Caval Replacement With Cadaveric Caval Graft for Living Donor Liver Transplantation in Budd-Chiari Syndrome Associated With Hydatid Cyst Surgery: A Case Report**

BALCI D., Kirimker O., Durdu S., HAZİNEDAROĞLU S. M., MEÇO B. C., ÖZÇELİK M., Yilmaz A. A., AKAR A. R., Kalkan C., İDİLMAN R., et al.

21st Annual International Congress of the International-Liver-Transplant-Society (ILTS), Illinois, United States Of America, 8 - 11 July 2015, vol.99, pp.247-248

- LXXXVI. **The role of genetic variability of pnpla3 (rs738409) on histological progression of non alcoholic fatty liver disease**

İdilman R., Keskin O., Karataylı S., Kabaçam G., Tüzün A. E., Savaş B., Elhan A. H., Bozdayı A. M.

24th Annual Conference of APASL, İstanbul, Turkey, 12 - 15 March 2015, pp.373

- LXXXVII. **The role of genetic variability of pnpla3 rs738409 on histological progression of non alcoholic fatty liver disease**

İDİLMAN R., KESKİN O., ÖZEN KARATAYLI S. C., KABAÇAM G., TÜZÜN A. E., SAVAŞ B., ELHAN A. H., BOZDAYI A. M.

24th Annual Conference of APASL, March 12-15, 2015, Istanbul, Turkey, 12 - 15 March 2015, vol.9, pp.373

- LXXXVIII. **Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy**

SOYDAL Ç., Keskin O., KÜÇÜK N. Ö., Bilgic S., ÖZKAN E., İDİLMAN R., KIR K. M.

Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), Missouri, United States Of America, 7 - 11 June 2014, vol.55

- LXXXIX. **Hepatoselüler kanserli hastalarda selektif internal radyasyon tedavisi sonrası sağkalımı öngörmede prognostik faktörler**

SOYDAL Ç., KESKİN O., KÜÇÜK N. Ö., İDİLMAN R., ÖZKAN E., BİLGİC M. S., KIR K. M.

26.Uluslararası Nükleer Tıp Kongresi, Turkey, 16 - 20 April 2014, pp.17

- XC. **Early on-treatment HDV RNA kinetics are not predictive for long-term response to a PEG-IFNa therapy of hepatitis delta**

- Wobse M., Yurdaydin C., Ernst S., Hardtke S., Heidrich B., Bremer B., Keskin O., İDİLMAN R., Koch A., Manns M. P., et al.
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 7 - 11 November 2014, vol.60
- XCI. The long-term efficacy of combination of nucleos(t)ide analogue treatment and low dose hepatitis b immunoglobulin on posttransplant HBV recurrence**
İDİLMAN R., Akyildiz M., Keskin O., Tuzun A., Yilmaz T. U., Guler N., Yaprak O., Gungor G., Erdogan Y., Dayangac M., et al.
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 7 - 11 November 2014, vol.60
- XCII. Prenylation inhibition with lonafarnib decreases hepatitis D levels in humans**
Koh C., Yurdaydin C., Cooper S., Cory D., Dahari H., Haynes-Williams V., Winters M. A., Bys M., Choong I. C., İDİLMAN R., et al.
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 7 - 11 November 2014, vol.60
- XCIII. Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF)**
Papatheodoridis G. V., Dalekos G. N., Sypsa V., Yurdaydin C., Buti M., Gouli I., Chi H., Manolakopoulos S., Mangia G., Gatselis N., et al.
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 7 - 11 November 2014, vol.60
- XCIV. Inactive hepatitis B carriers are prone to HBsAg loss rather than reactivation: a 5-year prospective follow-up study**
Keskin O., Yakut M., Kalkan C., Karatayli S. C., Karatayli E., İDİLMAN R., BOZDAYI A. M., Yurdaydin C.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58
- XCV. Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF)**
Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Gouli I., Arends P., Buti M., Sypsa V., Manolakopoulos S., Mangia G., Gatselis N., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58
- XCVI. Effectiveness and safety of entecavir and tenofovir in chronic hepatitis b patients: A multicenter Turkish study in clinical practice**
İDİLMAN R., GÜNSAR F., Keskin O., Meral C. E., KORUK M., GÜLŞEN M. T., ELHAN A. H., BOZDAYI A. M., AKARCA U. S., Yurdaydin C.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58
- XCVII. Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis**
Lampertico P., Soffredini R., Yurdaydin C., İDİLMAN R., Papatheodoridis G. V., Margariti E., Buti M., Esteban R., Zaltron S., Vavassori A., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58
- XCVIII. INTERLEUKIN-28 (IL-28) GENE POLYMORPHISM (RS12979860 C/T) IS ASSOCIATED WITH PROGRESSION TO CHRONIC DELTA HEPATITIS INFECTION**
BOZDAYI A. M., ÖZTÜRK T., Altuntas S., Karatayli S. C., Karatayli E., Celik I., ÇINAR K., ALBAYRAK DELİAL İOĞLU R., Ozkan M., İDİLMAN R., et al.
62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa

Rica, 4 - 08 November 2011, vol.54

- XCIX. IDENTIFICATION OF RISK FACTORS FOR FIBROSIS PROGRESSION IN NON-ALCOHOLIC FATTY LIVER DISEASE**
CENGİZ SEVAL G., İDİLMAN R., ÇINAR K., Seven G., Yakut M., Kabacam G., Evranos B., SAVAŞ B., Bahar K.
61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 29 October - 02 November 2010, vol.52
- C. HBsAg POZİTİF OLAN ALICILARDA ALLOJENİK HEMATOPOETİK HÜCRE TRANSPLANTASYONU**
TOPÇUOĞLU P., SOYDAN E., İDİLMAN R., CENGİZ SEVAL G., ÜSTÜN C., ARSLAN Ö., ÖZCAN M., KONUK N., İLHAN O., BEKSAÇ M., et al.
35. Ulusal Hematoloji Kongresi, 07 October 2009
- CI. RENAL TUBULER ACIDOSIS IN LIVER TRANSPLANT RECIPIENTS: THE EFFECT OF CALCINEURIN INHIBITORS.**
İDİLMAN R., KARASU A. Z., Cengiz G., KEVEN K., Ersoz S., ŞENGÜL Ş., Haznedaroglu S., TÜZÜNER A., Aydin U., Olut S., et al.
15th Annual Congress of the International-Liver-Transplantation-Society, New York, United States Of America, 8 - 11 July 2009, vol.15
- CII. The burden of chronic hepatitis B in a median endemic country:a mathematical approach**
TOY M., ÖNDER F. O., İDİLMAN R., Richardus J. H., BOZDAYI A. M., KULOĞLU Z., KANSU TANCA A., Yurdaydin C.
International Liver Congress TM 2009. 44th Annual Meeting of The European Association for the Study of the Liver,Copenhagen, Denmark, 22-26 April, 2009, Copenhagen, Denmark, 22 - 26 April 2009
- CIII. Kronik Viral Hepatitlerde Lenfoproliferatif Hastalıklar**
BOZKUŞ Y., İDİLMAN R., MIZRAK KAYA D., CENGİZ SEVAL G., Saykı M., Üstün Y., DOĞANAY ERDOĞAN B., BEKTAŞ M., ÇINAR K., ARAT M., et al.
25. Ulusal Gastroenteroloji Haftası, Turkey, 12 - 16 November 2008
- CIV. Kronik Hepatit C'li hastalarda karaciğer fibrozisini göstermede kullanılan biyokimyasal belirteçler ile karaciğer biyopsisinin tanısal değerliliklerinin karşılaştırılması**
MIZRAK KAYA D., İDİLMAN R., DOĞANAY ERDOĞAN B., SAVAŞ B., üstün y., Saykı M., BOZKUŞ Y., CENGİZ SEVAL G., BEKTAŞ M., Özden A.
25. Ulusal Gastroenteroloji Haftası, Turkey, 12 - 16 November 2008
- CV. Non-alkolik yağlı karaciğerde endotelyal fonksiyon ve kardiovasküler risk profili**
Saykı M., İDİLMAN R., TULUNAY KAYA C., MIZRAK KAYA D., Büyükkılıç Z., CENGİZ SEVAL G., BOZKUŞ Y., Üstün Y., BEKTAŞ M., DINÇER İ., et al.
25. Ulusal Gastroenteroloji Haftası, Turkey, 12 - 16 November 2008
- CVI. Non-Alkolik Yağlı Karaciğer: Uzun Süreli İlaçsız Takipte Doğal Seyir**
CENGİZ SEVAL G., İDİLMAN R., ÇINAR K., MIZRAK KAYA D., BOZKUŞ Y., Saykı M., Üstün Y., BEKTAŞ M., Erden E., Özden A.
25. Ulusal Gastroenteroloji Haftası, Turkey, 12 - 16 November 2008
- CVII. HBEAG-POSITIVE DELTA HEPATITIS: VIROLOGICAL; BIOCHEMICAL AND CLINICAL FEATURES IN A LARGE EUROPEAN MULTICENTER DATA BASE**
Heidrich B., Wedemeyer H., Bektas M., İDİLMAN R., Oender F. O., BOZDAYI A. M., Zachou K., Deterding K., Raupach R., Bozkaya H., et al.
59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San-Francisco, Costa Rica, 31 October - 04 November 2008, vol.48
- CVIII. Complete genome sequences and phylogenetic analysis of hepatitis D viruses (HDV) isolated from turkish patients with chronic HDV infection**
Emir F., Bektas M., Keser E., Idilman R., Bozdayi A. M., Yurdaydin C.
58th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 2 - 06 November 2007, vol.46
- CIX. Transjuguler Intrahepatik Portosistemik Santin Renal Resistivite indeksi Üzerine Etkileri: Erken Sonuçlar**
CENGİZ SEVAL G., İDİLMAN R., ÇINAR K., KEVEN K., ÇOBAN Ş., BEKTAŞ M., ÖZCAN H., ERGÜN İ., BAHAR D. K.,

- KARAYALÇIN S. S.
23. Ulusal Gastroenteroloji Kongresi, 05 November 2006
- CX. **Potential role of cytokine gene polymorphisms in outcome of chronic delta hepatitis**
Ulger Z., Emir F., Arslan-Ergul A., Idilman R., Yalcin K., Uzunalimoglu O., Bozkaya H., Bozdayi M. A., Yurdaydin C.
57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 27 - 31 October 2006, vol.44
- CXI. **Insulin-sensitizer agents in the treatment of individuals with non-alcoholic steatohepatitis: A preliminary report**
Idilman R., Mizrak D., Soykan I., Corapcioglu D., Erden E., Coban S., Bektas M., Uysal A. R., Emral R., Doganay B., et al.
57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 27 - 31 October 2006, vol.44
- CXII. **The fate of recipient-derived repopulated hepatocytes in sex-mismatched liver allograft: A longitudinal study**
Idilman R., Erden E., Ersoz S., Kuzu I., Karayalcin S.
56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San-Francisco, Costa Rica, 11 - 15 November 2005
- CXIII. **Treatment of chronic hepatitis D (CHD) with interferon vs. interferon plus lamivudine vs. lamivudine: Short-and long-term results**
Yurdaydin C., Bozkaya H., Onder O., Senturk H., Fried M., Idilman R., Cetinkaya H., Schinazi R., Bozdayi M., Uzunalimoglu O.
56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San-Francisco, Costa Rica, 11 - 15 November 2005, vol.42
- CXIV. **The effect of tissue injury on donor-derived hepatocyte repopulation following sex-mismatched hematopoietic stem cell transplantation**
Idilman R., Soykan I., Erden E., Kuzu I., Arat M., Akyol G., Akan H., BEKSAÇ M., Ozden A., Karayalcin S.
40th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Paris, France, 13 - 17 April 2005, vol.42, pp.139
- CXV. **The expression of intestinal trefoil factor in biliary epithelial cells of chronic graft-versus-host disease of the liver in allogeneic hematopoietic stem cell transplants**
Idilman R., Erden E., Arat M., Coban S., Erkan O., Tuzun A., Kuzu I., Bozdayi M., Akan H., Karayalcin S., et al.
40th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Paris, France, 13 - 17 April 2005, pp.236
- CXVI. **Potential role of cytokine gene polymorphisms in hepatitis B infection outcome**
Arslan-Ergul A., Yurdaydin C., Koytak E., Idilman R., Uzunalimoglu O., Bozdayi A., Bozkaya H.
40th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Paris, France, 13 - 17 April 2005, vol.42, pp.230
- CXVII. **The effects of transplantation-related factors and tissue injury on donor-derived cells repopulation following sex-mismatched haematopoietic cell transplantation**
Idilman R., Kuzu L., Arat M., Erden E., Soydan E., Soykan I., Akyol G., Karayalcin S., Akan H., BEKSAÇ M.
31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, Prague, Czech Republic, 20 - 23 March 2005, vol.35
- CXVIII. **PPAR-alpha L162V polymorphism in nonalcoholic steatohepatitis.**
Verdi H., Koytak E., Ergul A., Idilman R., Uzunalimoglu O., Yurdaydin C., Bozkaya H.
55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 29 October - 02 November 2004, vol.40
- CXIX. **Hepatit C Virus Enfeksiyonu Olan hastalarda Cinsel İşlev Bozuklukları**
BOZTAŞ M. H., İDİLMAN R., ÖZEL KIZIL E. T., TÜZÜN A. E., SOYKAN A., BOZKAYA H., YURDAYDIN C., KUMBASAR H., UZUNALIMOĞLU Ö., ÖZDEN A.
21. Ulusal Gastroenteroloji Kongresi, Turkey, 31 August - 04 September 2004
- CXX. **Recipient-derived hepatocytes in sex-mismatched liver allograft after liver transplantation**

- İdilman R., Erden E., Kuzu I., Ersoz S., Karayalcin K., KARASU A. Z., Tokat Y., Yuce G., Sahin Y., Bozkaya H., et al.
39th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Berlin, Germany, 14 - 18 April 2004,
pp.104
- CXXI. **Recipient-derived hepatocytes in sex-mismatched living-related partial liver transplants.**
İdilman R., Erden E., Kuzu I., Ersoz S., Karayalcin K., Yerdel M., Tukun A., Akyol G., Bozkaya H., Yurdaydin C., et al.
54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease, BOSTON, MASSACHUSETTS, 24 -
28 October 2003
- CXXII. **Lamivudine prophylaxis for prevention of chemotherapy induced hepatitis B virus reactivation in
hepatitis B virus carriers with hematological malignancies**
İdilman R., Arat M., TÖRÜNER M., Soykan I., Karayalcin S., Soydan E., Ozcan M., BEKSAÇ M., Arslan O., Akbulut H., et
al.
38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, İstanbul, Turkey, 29 March - 01 April
2003, vol.38, pp.146-147
- CXXIII. **The effect of hepatitis B virus status of the donor on the hepatitis B virus serology of the recipient
after allogeneic hematopoietic cell transplantation**
İdilman R., Soydan E., Arat M., TÖRÜNER M., Soykan I., Karayalcin S., Ustun C., Topcuoglu P., Ozcan M., Arslan O., et
al.
38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, İstanbul, Turkey, 29 March - 01 April
2003, vol.38, pp.146
- CXXIV. **The effect of mycophenolate mofetil in steroid refractory or dependent chronic graft-versus-host
disease**
Soydan E., Arat M., Topcuoglu P., Ozcan M., Arslan O., İdilman R., GÜRMAN G., BEKSAÇ M., Akan H., İlhan O.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT
Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31
- CXXV. **Donor type epithelial cell repopulation in gastrointestinal mucosa following sex mismatch allogeneic
peripheral blood transplantation: evidence for in vivo stem cell plasticity?**
Kuzu I., İdilman R., Arat M., Dalva K., Soykan I., Akan H., BEKSAÇ M.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT
Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003
- CXXVI. **The effect of hepatitis B virus status of donor on the hepatitis B virus serology of recipient after
allogeneic hematopoietic cell transplantation**
Soydan E., İdilman R., Arat M., Karayalcin S., Ustun C., Ozcan M., Arslan O., BEKSAÇ M., İlhan O., Akan H.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT
Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31
- CXXVII. **The efficiency of ursodeoxycholic acid in treatment of limited chronic graft versus host disease of
the liver.**
Arat M., İdilman R., Soydan E., TÖRÜNER M., Akan H.
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 December
2002, vol.100
- CXXVIII. **The long-term ursodeoxycholic acid treatment of chronic graft-versus-host disease of the liver.**
İdilman R., Arat M., TÖRÜNER M., Soydan E., Soykan I., Erden E., Karayalcin S., Ozcan M., Ustun C., Ozden A., et al.
53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD), BOSTON, MASSACHUSETTS, 1 -
05 November 2002, vol.36

Supported Projects

Elhan A. H., Özkan E., Soydal Ç., Tüzüner A., Araz M., Küçük N. Ö., İdilman R., Erden G. A., Gülpınar B., Kuru Öz D., Project
Supported by Higher Education Institutions, Evaluation of the clinical contribution of Ga-68 PSMA PET in hepatocellular
carcinoma (HCC) imaging, 2023 - 2025

İDİLMAN R., Project Supported by Higher Education Institutions, Alkol dışı yağlı karaciğer hastalığında kardiak ve

kardiovasküler hastalık varlığını önceden saptanması: Subklinik myokardial disfonksiyon, 2018 - 2020
İDİLMAN R., Project Supported by Other Official Institutions, PLASMA METABOLOMIC CHANGES MODULATE THE IMPACT OF MIDDLE EASTERN VERSUS WESTERN DIET IN AN INTERNATIONAL CIRRHOSIS COHORT, 2018 - 2018
İDİLMAN R., Other International Funding Programs, Protocol of the Predicting Acute on Chronic Liver Failure in Cirrhosis, 2017 - 2018

Metrics

Publication: 368

Citation (WoS): 5292

Citation (Scopus): 7901

H-Index (WoS): 36

H-Index (Scopus): 42